0000818479-22-000119 | 10-Q | XBRL Viewer

Print Document View Excel Document

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2022	Nov. 03, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	0-16211
Entity Registrant Name	DENTSPLY SIRONA Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	39-1434669
Entity Address, Address Line One	13320 Ballantyne Corporate Place
Entity Address, City or Town	Charlotte
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	28277-3607
City Area Code	844
Local Phone Number	848-0137
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	XRAY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Small Business Entity	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		214,911,886
Entity Central Index Key	0000818479
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net sales	$ 947	$ 1,040	$ 2,939	$ 3,128
Cost of products sold	439	471	1,329	1,385
Gross profit	508	569	1,610	1,743
Selling, general, and administrative expenses	401	395	1,187	1,174
Research and development expenses	41	39	131	122
Goodwill impairment	1,187	0	1,187	0
Intangible asset impairment and other costs	97	3	107	11
Operating (loss) income	(1,218)	132	(1,002)	436
Other income and expenses:
Interest expense, net	14	14	41	43
Other expense (income), net	9	5	20	4
(Loss) income before income taxes	(1,241)	113	(1,063)	389
(Benefit) provision for income taxes	(164)	29	(128)	97
Net (loss) income	(1,077)	84	(935)	292
Less: Net income attributable to noncontrolling interest	0	0	0	0
Net (loss) income attributable to Dentsply Sirona	$ (1,077)	$ 84	$ (935)	$ 292
Net (loss) income per common share attributable to Dentsply Sirona:
Basic (in dollars per share)	$ (5.01)	$ 0.39	$ (4.34)	$ 1.34
Diluted (in dollars per share)	$ (5.01)	$ 0.38	$ (4.34)	$ 1.32
Weighted average common shares outstanding:
Basic (in shares)	214.9	218.6	215.6	218.6
Diluted (in shares)	214.9	220.5	215.6	220.7

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (1,077)	$ 84	$ (935)	$ 292
Other comprehensive loss, net of tax:
Foreign currency translation loss	(148)	(68)	(310)	(130)
Net gain on derivative financial instruments	22	10	54	19
Pension liability gain	1	2	4	8
Total other comprehensive loss, net of tax	(125)	(56)	(252)	(103)
Total comprehensive (loss) income	(1,202)	28	(1,187)	189
Less: Comprehensive income attributable to noncontrolling interests	0	0	0	0
Total comprehensive (loss) income attributable to Dentsply Sirona	$ (1,202)	$ 28	$ (1,187)	$ 189

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current Assets:
Cash and cash equivalents	$ 418	$ 339
Accounts and notes receivables-trade, net	645	750
Inventories, net	592	515
Prepaid expenses and other current assets	284	248
Total Current Assets	1,939	1,852
Property, plant, and equipment, net	714	773
Operating lease right-of-use assets, net	201	198
Identifiable intangible assets, net	1,875	2,319
Goodwill	2,584	3,976
Other noncurrent assets	209	121
Total Assets	7,522	9,239
Current Liabilities:
Accounts payable	271	262
Accrued liabilities	711	760
Income taxes payable	68	57
Notes payable and current portion of long-term debt	246	182
Total Current Liabilities	1,296	1,261
Long-term debt	1,737	1,913
Operating lease liabilities	154	149
Deferred income taxes	246	391
Other noncurrent liabilities	475	528
Total Liabilities	3,908	4,242
Commitments and contingencies (Note 15)
Equity:
Preferred stock, $1.00 par value; 0.25 million shares authorized; no shares issued	0	0
Common stock, $0.01 par value; 400.0 million shares authorized, and 264.5 million shares issued at September 30, 2022 and December 31, 2021 214.9 million and 217.4 million shares outstanding at September 30, 2022 and December 31, 2021	3	3
Capital in excess of par value	6,619	6,606
Retained earnings	498	1,514
Accumulated other comprehensive loss	(844)	(592)
Treasury stock, at cost, 49.6 million and 47.1 million shares at September 30, 2022 and December 31, 2021, respectively	(2,663)	(2,535)
Total Dentsply Sirona Equity	3,613	4,996
Noncontrolling interests	1	1
Total Equity	3,614	4,997
Total Liabilities and Equity	$ 7,522	$ 9,239

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Equity:
Preferred stock, par value (in dollars per share)	$ 1	$ 1
Preferred stock, shares authorized (in shares)	250,000	250,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	400,000,000	400,000,000
Common stock, shares issued (in shares)	264,500,000	264,500,000
Common stock, shares outstanding (in shares)	214,900,000	217,400,000
Treasury stock, shares (in shares)	49,600,000	47,100,000

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Millions	Total	Total Dentsply Sirona Equity	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Loss	Treasury Stock	Noncontrolling Interests
Beginning Balance at Dec. 31, 2020	$ 4,935	$ 4,932	$ 3	$ 6,604	$ 1,198	$ (464)	$ (2,409)	$ 3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	112	112			112
Other Comprehensive (loss) income	(90)	(90)				(90)
Exercise of stock options	33	33		11			22
Stock based compensation expense	13	13		13
Funding of employee stock purchase plan	3	3		1			2
Treasury shares purchased	(90)	(90)					(90)
Restricted stock unit distributions	(4)	(4)		(11)			7
Cash dividends	(22)	(22)			(22)
Ending Balance at Mar. 31, 2021	4,890	4,887	3	6,618	1,288	(554)	(2,468)	3
Beginning Balance at Dec. 31, 2020	4,935	4,932	3	6,604	1,198	(464)	(2,409)	3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	292
Other Comprehensive (loss) income	(103)
Ending Balance at Sep. 30, 2021	5,063	5,060	3	6,659	1,419	(567)	(2,454)	3
Beginning Balance at Mar. 31, 2021	4,890	4,887	3	6,618	1,288	(554)	(2,468)	3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	96	96			96
Other Comprehensive (loss) income	43	43				43
Exercise of stock options	12	12		3			9
Stock based compensation expense	19	19		19
Restricted stock unit distributions	(1)	(1)		(2)			1
Cash dividends	(25)	(25)			(25)
Ending Balance at Jun. 30, 2021	5,034	5,031	3	6,638	1,359	(511)	(2,458)	3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	84	84			84			0
Other Comprehensive (loss) income	(56)	(56)				(56)
Exercise of stock options	1	1					1
Stock based compensation expense	23	23		23
Funding of employee stock purchase plan	3	3		1			2
Restricted stock unit distributions	(3)	(3)		(4)			1
Restricted stock unit dividends	0	0		1	(1)
Cash dividends	(23)	(23)			(23)
Ending Balance at Sep. 30, 2021	5,063	5,060	3	6,659	1,419	(567)	(2,454)	3
Beginning Balance at Dec. 31, 2021	4,997	4,996	3	6,606	1,514	(592)	(2,535)	1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	69	69			69
Other Comprehensive (loss) income	(37)	(37)				(37)
Exercise of stock options	5	5		1			4
Stock based compensation expense	11	11		11
Funding of employee stock purchase plan	2	2		1			1
Accelerated share repurchase	(150)	(150)		(30)			(120)
Restricted stock unit distributions	(6)	(6)		(16)			10
Cash dividends	(27)	(27)			(27)
Ending Balance at Mar. 31, 2022	4,864	4,863	3	6,573	1,556	(629)	(2,640)	1
Beginning Balance at Dec. 31, 2021	4,997	4,996	3	6,606	1,514	(592)	(2,535)	1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(935)
Other Comprehensive (loss) income	(252)
Ending Balance at Sep. 30, 2022	3,614	3,613	3	6,619	498	(844)	(2,663)	1
Beginning Balance at Mar. 31, 2022	4,864	4,863	3	6,573	1,556	(629)	(2,640)	1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	73	73			73
Other Comprehensive (loss) income	(90)	(90)				(90)
Exercise of stock options	2	2					2
Stock based compensation expense	16	16		16
Funding of employee stock purchase plan	1	1					1
Accelerated share repurchase	0	0		30			(30)
Restricted stock unit distributions	(2)	(2)		(3)			1
Restricted stock unit dividends				1	(1)
Cash dividends	(26)	(26)			(26)
Ending Balance at Jun. 30, 2022	4,838	4,837	3	6,617	1,602	(719)	(2,666)	1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(1,077)	(1,077)			(1,077)
Other Comprehensive (loss) income	(125)	(125)				(125)
Stock based compensation expense	3	3		3
Funding of employee stock purchase plan	3	3					3
Restricted stock unit distributions	(1)	(1)		(1)
Restricted stock unit dividends	0	0
Cash dividends	(27)	(27)			(27)
Ending Balance at Sep. 30, 2022	$ 3,614	$ 3,613	$ 3	$ 6,619	$ 498	$ (844)	$ (2,663)	$ 1

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021
Statement of Stockholders' Equity [Abstract]
Cash dividends (in dollars per share)	$ 0.125	$ 0.125	$ 0.125	$ 0.11	$ 0.11	$ 0.1

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net (loss) income	$ (935)	$ 292
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	90	94
Amortization of intangible assets	159	167
Goodwill impairment	1,187	0
Indefinite-lived intangible asset impairment	94	0
Deferred income taxes	(220)	(11)
Stock based compensation expense	47	54
Other non-cash expense	38	13
Gain on sale of non-strategic businesses and product lines	0	(14)
Changes in operating assets and liabilities, net of acquisitions:
Accounts and notes receivable-trade, net	43	(89)
Inventories, net	(140)	(88)
Prepaid expenses and other current assets, net	(46)	(24)
Other noncurrent assets	(13)	(12)
Accounts payable	40	(45)
Accrued liabilities	(2)	70
Income taxes	41	6
Other noncurrent liabilities	(8)	22
Net cash provided by operating activities	375	435
Cash flows from investing activities:
Capital expenditures	(117)	(101)
Cash paid for acquisitions of businesses and equity investments, net of cash acquired	0	(248)
Cash received on sale of non-strategic businesses or product lines	0	27
Cash received on derivative contracts	10	1
Other investing activities	(2)	2
Net cash used in investing activities	(109)	(319)
Cash flows from financing activities:
Cash paid for accelerated share repurchase	(150)	0
Proceeds on short-term borrowings	64	147
Cash paid for treasury stock	0	(90)
Cash dividends paid	(78)	(68)
Proceeds from long-term borrowings, net of deferred financing costs	7	15
Repayments on long-term borrowings	(2)	(297)
Proceeds from exercised stock options	6	47
Other financing activities, net	(15)	(11)
Net cash used in financing activities	(168)	(257)
Effect of exchange rate changes on cash and cash equivalents	(19)	(16)
Net increase (decrease) in cash and cash equivalents	79	(157)
Cash and cash equivalents at beginning of period	339	438
Cash and cash equivalents at end of period	$ 418	$ 281

SIGNIFICANT ACCOUNTING POLICIES AND RESTATEMENT	9 Months Ended
SIGNIFICANT ACCOUNTING POLICIES AND RESTATEMENT	Sep. 30, 2022
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES AND RESTATEMENT	SIGNIFICANT ACCOUNTING POLICIES AND RESTATEMENT Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries (“Dentsply Sirona” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form 10-K/A for the year ended December 31, 2021, as amended and filed on November 7, 2022. Recently Concluded Investigation As previously disclosed, the Audit and Finance Committee of the Company's Board of Directors (the "Audit and Finance Committee"), assisted by independent legal counsel and forensic accountants, commenced an internal investigation in March 2022 of allegations regarding certain financial reporting matters submitted by current and former employees of the Company. The investigation was conducted in two components, one pertaining to allegations regarding the Company’s use of incentives to sell products to certain distributors in North America in the third and fourth quarters of 2021 (the "North American Investigation") and another to analyze the increase in returns of products in China during the fourth quarter of 2021 identified by the Company (the "China Investigation"). In the North America Investigation, the Audit and Finance Committee concluded that there was no evidence of intentional wrongdoing or fraud. The Audit and Finance Committee found that certain former members of senior management, including the Company's former Chief Executive Officer and former Chief Financial Officer, violated provisions of the Company's Code of Ethics and Business Conduct. In addition, these former members of senior management did not maintain and promote an appropriate control environment focused on compliance in areas of the Company’s business, nor did they sufficiently promote, monitor or enforce adherence to the Code of Ethics and Business Conduct. The North America Investigation found that certain former members of senior management, including the former Chief Executive Officer and the former Chief Financial Officer created a culture where employees did not feel comfortable raising concerns without fear of retaliation. In addition, the North America Investigation substantiated certain allegations regarding inappropriate tone at the top by the former Chief Executive Officer and the former Chief Financial Officer. Based on the China Investigation, the Audit and Finance Committee concluded that members of the Company's local commercial team in China, as well as the head of the Company's Asia-Pacific commercial organization, committed intentional wrongdoing by failing to provide requested information to the Company's local accounting team, by obstructing the work of the accounting team and by lacking truthfulness in providing information to the Company and to the Audit and Finance Committee as part of the China Investigation. The China Investigation also determined that these actions by the certain members of the Company's local commercial team in China, as well as the former Chief Financial Officer and the head of the Company's Asia-Pacific commercial organization, violated the Company's Code of Ethics and Business Conduct. On October 29, 2022, the Audit and Finance Committee determined that its investigation was complete. Prior Restatement and Other Corrections of Previously Issued Consolidated Financial Statements The interim consolidated financial statements include previously-made corrections to the three-month and nine-month periods ended September 30, 2021 which were presented in Note 1 to the interim consolidated financial statements and notes thereto for these same periods in the Company's Form 10-Q/A filed on November 7, 2022. This restatement corrected for errors related to certain customer incentive programs as well as the accounting and assumptions in the determination of estimates related to the Company’s sales returns provisions, warranty reserve provisions and variable consideration. In addition, a failure to appropriately account for certain product returns and/or exchanges identified as part of the China investigation referred to above resulted in an overstatement of Net sales in the third quarter of 2021 of approximately $4 million which should have been recorded in the fourth quarter of 2021, and was also reflected in the restated interim financial statements for the three and nine month periods ended September 30, 2021. In conjunction with making these corrections, the Company has also made certain other restatements and revisions for previously identified errors. The restatement from these collective errors resulted in a decrease to Net sales by $29 million, a decrease to Gross profit by $22 million, a decrease to Operating income of $27 million and a decrease to Diluted EPS by $0.09 per share from amounts previously reported for the three-month period ended September 30, 2021. The restatement resulted in a decrease to Net sales by $35 million, a decrease to Gross profit by $25 million, a decrease to Operating income of $32 million and a decrease to Diluted EPS by $0.13 per share from amounts previously reported for the nine-month period ended September 30, 2021. In order to correct these errors, management previously restated the Company's consolidated financial statements as of and for the three and nine months ended September 30, 2021 which are presented as the comparative periods in the accompanying consolidated financial statements, and also restated as necessary the comparative periods presented in the related notes included herein to correct these accounting errors. For details of these restatements on the previously issued financial statements for these periods, refer to Note 1 of the interim consolidated financial statements in the Company's Form 10-Q/A filed on November 7, 2022. The Company also restated its consolidated financial statements for the fiscal year ended December 31, 2021 in its Form 10-K/A filed on November 7, 2022. Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of Net sales and expense during the reporting period. Actual results could differ materially from those estimates. Specifically, for the three months ended September 30, 2022, some of these estimates and assumptions continue to be based on an ongoing evaluation of expected future impacts from the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly have a negative material impact on the Company's financial condition, liquidity, or results of operations in future periods is highly uncertain and difficult to predict. More specifically, although demand for the Company’s products has largely recovered from the impact of rigorous preventive measures implemented at the outset of the pandemic, it continues to be affected by social distancing guidelines, dental practice safety protocols which reduce patient traffic, and some lingering patient reluctance to seek dental care. Also, impacts from the pandemic continue to be experienced in the form of shortages for specific materials such as electronic components, higher related transportation costs, and labor shortages. Throughout 2022, the Company has continued to experience supply chain constraints, which has impacted its ability to timely produce and deliver certain products, and has also resulted in increases in shipping rates. In the third quarter the Company has been further impacted by deteriorating macroeconomic conditions more generally, including rising global interest rates and inflationary pressures which have raised the price of inputs, impacted the discretionary spending behavior of our customers, and introduced new competitive challenges. To address these issues, the Company has taken steps to mitigate the impact of these trends, including continued emphasis on cost reduction and supply chain efficiencies. However, uncertainties remain regarding how long these impacts will continue or whether future variants of the virus may have an adverse impact in affected markets. Accounting Pronouncements Not Yet Adopted In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU No. 2020-04 "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which was subsequently amended by ASU No. 2021-01 "Reference Rate Reform (Topic 848): Scope" in January 2021. The new standard provides optional expedients and exceptions to contracts, hedging relationships, and other transactions that reference the London Interbank Offer Rate ("LIBOR") or another rate expected to be discontinued due to the reference rate reform. The amendments in this standard were effective upon issuance and generally can be applied to contract modifications made or evaluated through December 31, 2022. The Company does not expect this standard to have a material impact on its consolidated financial statements and related disclosures. In October 2021, the FASB issued ASU No. 2021-08, "Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (Topic 805)", which requires contract assets and liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value differs from the current approach. This standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures. Seasonality Our business is subject to seasonal fluctuations. Our sales and profits are typically the highest during the third and fourth quarters due to DS World, our annual dental conference, which historically has occurred near the end of September. As a result, a disproportionate amount of operating cash flows is generated in the fourth quarter of our fiscal year. Despite a significant portion of these sales occurring in the third and fourth quarter, there are operating expenses, principally advertising and promotional expenses, throughout the year. Because of the seasonal nature of the Company's business, the results of operations for any fiscal quarter will not necessarily be indicative of results to be expected for other quarters or a full fiscal year.

REVENUE

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

REVENUE

Revenues are derived primarily from the sale of dental equipment and dental and healthcare consumable products. Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.

Net sales disaggregated by product category for the three and nine months ended September 30, 2022 and 2021 were as follows:


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Equipment & Instruments	$	163	$	176	$	498	$	523
CAD/CAM	116		147		351		403
Orthodontics	76		63		220		212
Implants	135		150		439		461
Healthcare	66		76		208		225
Technology & Equipment segment revenue	$	556	$	612	$	1,716	$	1,824

Endodontic & Restorative	$	282	$	313	$	887	$	953
Other Consumables	109		115		336		351
Consumables segment revenue	$	391	$	428	$	1,223	$	1,304

Total net sales	$	947	$	1,040	$	2,939	$	3,128

Net sales disaggregated by geographic region for the three and nine months ended September 30, 2022 and 2021 were as follows:


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

United States	$	357	$	384	$	1,023	$	1,094
Europe	358		393		1,183		1,239
Rest of World	232		263		733		795

Total net sales	$	947	$	1,040	$	2,939	$	3,128

Contract Assets and Liabilities

The Company normally does not have contract assets in the course of its business. Contract liabilities, which represent billings in excess of revenue recognized, are primarily related to advanced billings for customer aligner treatment where the performance obligation has not yet been fulfilled. The Company had $74 million and $68 million of deferred revenue recorded in Accrued liabilities in the Consolidated Balance Sheets at September 30, 2022 and December 31, 2021, respectively. The Company recognized revenue deferred as of December 31, 2021 of approximately $48 million during the current year. The Company expects to recognize significantly all of the remaining deferred revenue within the next twelve months.

Allowance for Doubtful Accounts

Accounts and notes receivables-trade, net are stated net of allowances for doubtful accounts and trade discounts, which were $9 million at September 30, 2022 and $13 million at December 31, 2021. For the three months and nine months ended September 30, 2022 and 2021, changes to the provision for doubtful accounts including write-offs of accounts receivable that were previously reserved were insignificant. Changes to this provision are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

STOCK COMPENSATION

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

STOCK COMPENSATION

The amounts of stock compensation expense recorded in the Company's Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021 were as follows:


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Cost of products sold	$	1	$	2	$	2	$	4
Selling, general, and administrative expense	12		19		43		48
Research and development expense	1		1		2		2
Total stock based compensation expense	$	14	$	22	$	47	$	54

Related deferred income tax benefit	$	1	$	2	$	4	$	6

COMPREHENSIVE INCOME (LOSS)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

COMPREHENSIVE INCOME (LOSS)

Changes in Accumulated other comprehensive income (loss) ("AOCI"), net of tax, by component for the nine months ended September 30, 2022 and 2021 were as follows:



(in millions)	Foreign Currency Translation Gain (Loss)		Gain (Loss) on Cash Flow Hedges		Gain (Loss) on Net Investment and Fair Value Hedges		Pension Liability Gain (Loss)		Total

Balance, net of tax, at December 31, 2021	$	(366)	$	(16)	$	(103)	$	(107)	$	(592)
Other comprehensive (loss) income before reclassifications and tax impact	(37)		3		9		—		(25)
Tax expense	(11)		—		(1)		—		(12)
Other comprehensive (loss) income, net of tax, before reclassifications	(48)		3		8		—		(37)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		(1)		—		1		—
Net (decrease) increase in other comprehensive income	(48)		2		8		1		(37)


Balance, net of tax, at March 31, 2022	$	(414)	$	(14)	$	(95)	$	(106)	$	(629)
Other comprehensive (loss) income before reclassifications and tax impact	(86)		(3)		32		—		(57)
Tax expense	(28)		—		(8)		—		(36)
Other comprehensive (loss) income, net of tax, before reclassifications	(114)		(3)		24		—		(93)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		1		—		2		3
Net (decrease) increase in other comprehensive income	(114)		(2)		24		2		(90)


Balance, net of tax, at June 30, 2022	$	(528)	$	(16)	$	(71)	$	(104)	$	(719)
Other comprehensive (loss) income before reclassifications and tax impact	(120)		3		28		—		(89)
Tax expense	(28)		(1)		(7)		—		(36)
Other comprehensive (loss) benefit, net of tax, before reclassifications	(148)		2		21		—		(125)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		(1)		—		1		—
Net (decrease) increase in other comprehensive income	(148)		1		21		1		(125)


Balance, net of tax, at September 30, 2022	$	(676)	$	(15)	$	(50)	$	(103)	$	(844)


(in millions)	Foreign Currency Translation Gain (Loss)		Gain (Loss) on Cash Flow Hedges		Gain (Loss) on Net Investment and Fair Value Hedges		Pension Liability Gain (Loss)		Total

Balance, net of tax, at December 31, 2020	$	(187)	$	(25)	$	(119)	$	(133)	$	(464)
Other comprehensive (loss) income before reclassifications and tax impact	(74)		(6)		9		3		(68)
Tax (expense) benefit	(25)		2		(2)		(1)		(26)
Other comprehensive (loss) income, net of tax, before reclassifications	(99)		(4)		7		2		(94)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		2		—		2		4
Net (decrease) increase in other comprehensive income	(99)		(2)		7		4		(90)
Balance, net of tax, at March 31, 2021	$	(286)	$	(27)	$	(112)	$	(129)	$	(554)
Other comprehensive income before reclassifications and tax impact	31		3		1		—		35
Tax benefit (expense)	6		(2)		(1)		—		3
Other comprehensive income, net of tax, before reclassifications	37		1		—		—		38
Amounts reclassified from accumulated other comprehensive income, net of tax	—		3		—		2		5
Net increase in other comprehensive income	37		4		—		2		43

Balance, net of tax, at June 30, 2021	$	(249)	$	(23)	$	(112)	$	(127)	$	(511)
Other comprehensive (loss) income before reclassifications and tax impact	(59)		6		3		—		(50)
Tax expense	(9)		(1)		(1)		—		(11)
Other comprehensive (loss) income, net of tax, before reclassifications	(68)		5		2		—		(61)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		3		—		2		5
Net (decrease) increase in other comprehensive income	(68)		8		2		2		(56)
Balance, net of tax, at September 30, 2020	$	(317)	$	(15)	$	(110)	$	(125)	$	(567)

At September 30, 2022 and December 31, 2021, the cumulative tax adjustments were $84 million and $168 million, respectively, primarily related to foreign currency translation adjustments.

The cumulative foreign currency translation adjustments included translation losses of $639 million and $250 million at September 30, 2022 and December 31, 2021, respectively, and cumulative losses on loans designated as hedges of net investments of $37 million and $116 million, respectively. These foreign currency translation losses were partially offset by movements on derivative financial instruments.

Reclassifications out of AOCI to the Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021 were not significant.

EARNINGS PER COMMON SHARE

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

EARNINGS PER COMMON SHARE

The computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2022 and 2021 were as follows:


Basic Earnings Per Common Share	Three Months Ended				Nine Months Ended
(in millions, except per share amounts)	2022		2021		2022		2021

Net (loss) income attributable to Dentsply Sirona	$	(1,077)	$	84	$	(935)	$	292

Weighted average common shares outstanding	214.9		218.6		215.6		218.6

(Loss) earnings per common share - basic	$	(5.01)	$	0.39	$	(4.34)	$	1.34

Diluted Earnings Per Common Share	Three Months Ended				Nine Months Ended
(in millions, except per share amounts)	2022		2021		2022		2021

Net (loss) income attributable to Dentsply Sirona	$	(1,077)	$	84	$	(935)	$	292

Weighted average common shares outstanding	214.9		218.6		215.6		218.6
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	—		1.9		—		2.1
Total weighted average diluted shares outstanding	214.9		220.5		215.6		220.7

(Loss) earnings per common share - diluted	$	(5.01)	$	0.38	$	(4.34)	$	1.32

The calculation of weighted average diluted common shares outstanding excluded 0.3 million and 0.5 million of potentially diluted common shares because the Company reported a net loss for the three months ended and nine months ended September 30, 2022, respectively.

For the three and nine months ended September 30, 2022, the Company excluded from the computation of weighted average diluted shares outstanding 3.6 million of equivalent shares of common stock from stock options and RSUs because their effect would be antidilutive. For the three and nine months ended September 30, 2021, the Company excluded 0.9 million and 0.9 million of equivalent shares of common stock outstanding from stock options and RSUs, respectively, because their effect would be antidilutive.

The Board of Directors has approved a share repurchase program, of up to $1.0 billion. Share repurchases may be made through open market purchases, Rule 10b5-1 plans, accelerated share repurchases, privately negotiated transactions or other transactions in such amounts and at such times as the Company deems appropriate based upon prevailing market and business conditions and other factors. At September 30, 2022, the Company had authorization to repurchase $740 million in shares of common stock remaining under the share repurchase program.

On March 8, 2022, the Company entered into an Accelerated Share Repurchase Agreement ("ASR Agreement") with a financial institution to purchase the Company's common stock based on the volume-weighted average price of the Company's common stock during the term of the agreement, less a discount.


(in millions, except per share amounts)			Initial Delivery					Final Settlement
Agreement Date	Amount Paid		Shares Received	Price per share		Value of Shares as a % of Contract Value		Settlement Date	Total Shares Received	Average Price per Share
March 8, 2022	$	150	2.4	$	50.44	80	%	April 19, 2022	3.1	$	48.22

The ASR agreement was accounted for as an initial delivery of common shares in a treasury stock transaction on March 9, 2022 of $120 million and a forward contract indexed to the Company's common stock for an amount of common shares to be determined on the final settlement date. The forward contract met all applicable criteria for equity classification and was not accounted for as a derivative instrument. Therefore, the forward contract was recorded as Capital in excess of par value and upon final settlement was recorded as Treasury Stock in the Consolidated Balance Sheets at September 30, 2022. The initial delivery and final settlement of common stock reduced the weighted average common shares outstanding for both basic and diluted EPS. The forward contract did not impact the weighted average common shares outstanding for diluted EPS.

BUSINESS COMBINATIONS

9 Months Ended

Sep. 30, 2022

Business Combination and Asset Acquisition [Abstract]

BUSINESS COMBINATIONS

Acquisitions

2021 Transactions

On July 1, 2021, the effective date of the transaction, the Company paid $7 million to acquire the remaining interest in the dental business of a partially owned affiliate based in Switzerland that primarily develops highly specialized software with a focus on CAD/CAM systems. The acquisition is expected to further accelerate the development of the Company's specialized software related to CAD/CAM systems.

The fair values of the assets acquired and liabilities assumed in connection with the acquisition of the affiliate included $4 million of Other current assets, $3 million of Intangible assets, $2 million of Current Liabilities and $1 million of Other long-term liabilities. The cash paid and the $4 million fair value of the previously-held interest in the entity prior to the acquisition has been allocated on the basis of the estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $7 million in goodwill. This goodwill is considered to represent the value associated with the acquired workforce and synergies the Company anticipates realizing from integrating the acquired assets into the Company's existing business operations, and is not deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 and the nine months ended September 30, 2022 were immaterial to the financial statements, resulting in an increase to goodwill of $2 million.

Identifiable intangible assets acquired were as follows:

Weighted Average

Useful Life

(in millions, except for useful life)

Amount

(in years)

In-process R&D

Indefinite

On June 1, 2021, the effective date of the transaction, the Company paid $132 million to acquire substantially all of the assets of Propel Orthodontics LLC and certain of its affiliated entities, a privately-held business based in California ("Propel Orthodontics"). The acquired business manufactures and sells orthodontic devices and provides in-office and at-home orthodontic accessory devices to orthodontists and their patients primarily within the clear aligner market. The acquisition is expected to further accelerate the growth and profitability of the Company's combined clear aligners business.

The fair values of the assets acquired and liabilities assumed in connection with the Propel Orthodontics acquisition were as follows:


(in millions)


Other current assets	$	4
Intangible assets	66
Current liabilities	(1)
Net assets acquired	69
Goodwill	63
Purchase consideration	$	132

The purchase price has been allocated on the basis of the estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $63 million in goodwill, which is considered to represent the value associated with the acquired workforce and synergies the Company anticipates realizing from integrating the acquired assets into the Company's existing business operations. The goodwill is expected to be deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 and the nine months ended September 30, 2022 were immaterial to the financial statements, resulting in a reduction to goodwill of $2 million.

Identifiable intangible assets acquired were as follows:

Weighted Average

Useful Life

(in millions, except for useful life)

Amount

(in years)

Developed technology

On January 21, 2021, the effective date of the transaction, the Company paid $94 million with the potential for additional earn-out provision payments of up to $10 million, to acquire 100% of the outstanding shares of Datum Dental, Ltd. ("Datum"), a privately-held producer and distributor of specialized regenerative dental material based in Israel. The fair value of the earn-out provision has been valued at $9 million as of the transaction date, resulting in a total purchase price of $103 million.

The fair values of the assets acquired and liabilities assumed in connection with the Datum acquisition were as follows:


(in millions)

Cash and cash equivalents	$	2
Other current assets	2
Intangible assets	76
Current liabilities	(2)
Other long-term assets (liabilities), net	(14)
Net assets acquired	64
Goodwill	39
Purchase consideration	$	103

The purchase price has been allocated on the basis of the estimates of fair values of assets acquired and liabilities assumed, resulting in the recording of $39 million in goodwill, which is considered to represent the value associated with the acquired workforce and synergies the Company anticipates realizing from integrating the acquired assets into the Company's existing business operations. The goodwill is not deductible for tax purposes. Measurement period adjustments made to the fair values of the assets acquired and liabilities assumed during the year ended December 31, 2021 and the nine months ended September 30, 2022 were immaterial to the financial statements, resulting in an increase to goodwill of $6 million.

Identifiable intangible assets acquired were as follows:


			Weighted Average
			Useful Life
(in millions, except for useful life)	Amount		(in years)

Developed technology	$	66	15
In-process R&D	10		Indefinite
Total	$	76

In the nine months ended September 30, 2022, certain earn-out provisions were achieved and the Company made cash payments of $5 million to the former shareholders of Datum with no impact to the Company's Statement of Operations for the period. As of September 30, 2022, the remaining contingent consideration obligation was $4 million.

The results of operations for each of the acquired businesses above upon the effective date of each transaction have been included in the accompanying financial statements. These results, as well as the historical results for the above acquired businesses for the periods ended September 30, 2022 and September 30, 2021, are not material in relation to the Company’s net sales and earnings for those periods. The Company therefore does not believe these acquisitions represent material transactions either individually or in the aggregate requiring the supplemental pro-forma information prescribed by ASC 805 and accordingly, this information is not presented.

Investment in Affiliates

On June 4, 2021, the effective date of the transaction, the Company paid $16 million to acquire a minority interest in a U.K.-based, privately-held provider of healthcare consumables. The investment is recorded as an equity method investment within Other noncurrent assets in the Consolidated Balance Sheets.

Divestitures

On April 1, 2021, the Company disposed of certain orthodontics businesses based in Japan previously included as part of the Technologies & Equipment segment in exchange for a cash receipt of $8 million. The divestiture resulted in an immaterial loss recorded in Other expense (income), net in the Consolidated Statements of Operations for the nine months ended September 30, 2021.

On February 1, 2021, the Company disposed of an investment casting business previously included as part of the Consumables segment in exchange for a cash receipt of $19 million. The divestiture resulted in a pre-tax gain of $13 million recorded in Other expense (income), net in the Consolidated Statements of Operations for the nine months ended September 30, 2021.

SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

SEGMENT INFORMATION

The Company’s two operating segments are organized primarily by product and generally have overlapping geographical presence, customer bases, distribution channels, and regulatory oversight. These operating segments are also the Company’s reportable segments in accordance with how the Company’s chief operating decision-maker regularly reviews financial results and uses this information to evaluate the Company’s performance and allocate resources.

The Company evaluates performance of the segments based on net sales and adjusted operating income. Segment adjusted operating income is defined as operating income before income taxes and before certain corporate headquarters unallocated costs, goodwill impairments, intangible asset impairments and other costs, interest expense, net, other expense (income), net, amortization of intangible assets and depreciation resulting from the fair value step-up of property, plant, and equipment from acquisitions.

A description of the products and services provided within each of the Company’s two reportable segments is provided below.

Technologies & Equipment

This segment is responsible for the design, manufacture, and sales of the Company’s dental technology and equipment products and healthcare products. These products include dental implants, CAD/CAM systems, orthodontic clear aligners, imaging systems, treatment centers, instruments, as well as medical devices.

Consumables

This segment is responsible for the design, manufacture, and sales of the Company’s consumable products which include various preventive, restorative, endodontic, and dental laboratory products.

The Company’s segment information for the three and nine months ended September 30, 2022 and 2021 was as follows:

Net Sales


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Technologies & Equipment	$	556	$	612	$	1,716	$	1,824
Consumables	391		428		1,223		1,304
Total net sales	$	947	$	1,040	$	2,939	$	3,128

Segment Adjusted Operating Income


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Technologies & Equipment	$	73	$	134	$	278	$	391
Consumables	121		123		398		426
Segment adjusted operating income	194		257		676		817

Reconciling items expense (income):
All other (a)	77		67		223		199
Goodwill impairment	1,187		—		1,187		—
Intangible asset impairment and other costs	97		3		107		11
Interest expense, net	14		14		41		43

Other expense (income), net	9		5		20		4
Amortization of intangible assets	51		56		159		167
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations	—		(1)		2		4
(Loss) income before income taxes	$	(1,241)	$	113	$	(1,063)	$	389

(a) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

INVENTORIES

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

INVENTORIES

Inventories, net were as follows:


(in millions)	September 30, 2022		December 31, 2021

Raw materials and supplies	$	142	$	139
Work-in-process	70		72
Finished goods	380		304
Inventories, net	$	592	$	515

The Company's inventory reserve was $77 million and $86 million at September 30, 2022 and December 31, 2021, respectively. Inventories are stated at the lower of cost and net realizable value.

INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS

9 Months Ended

Sep. 30, 2022

Restructuring and Related Activities [Abstract]

INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS

Intangible asset impairment and other costs for the three and nine months ended September 30, 2022 and 2021 were as follows:


Affected Line Item in the Consolidated Statements of Operations	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Cost of products sold	$	—	$	—	$	—	$	(3)
Selling, general, and administrative expenses	—		3		—		6
Intangible asset impairment and other costs	97		3		107		11

Total intangible asset impairment and other costs	$	97	$	6	$	107	$	14

For the three and nine months ended September 30, 2022, the above costs include an impairment charge of $94 million related to indefinite-lived tradenames and trademarks within the Technologies & Equipment segment and the Consumables segment. For more information on this impairment charge, refer to Note 14 Goodwill and Intangible Assets.

Other costs for these periods include severance and other expense related to the Company's restructuring plans. The Company’s restructuring accruals at September 30, 2022 were as follows:


	Severance
(in millions)	2020 and Prior Plans		2021 Plans		2022 Plans		Total

Balance at December 31, 2021	$	5	$	9	$	—	$	14
Provisions	1		1		8		10
Amounts applied	(3)		(5)		(3)		(11)
Change in estimates	(1)		—		—		(1)
Balance at September 30, 2022	$	2	$	5	$	5	$	12


	Other Restructuring Costs
(in millions)	2020 and Prior Plans		2021 Plans		2022 Plans		Total

Balance at December 31, 2021	$	4	$	—	$	—	$	4
Provisions	1		1		1		3
Amounts applied	(4)		(1)		(1)		(6)

Balance at September 30, 2022	$	1	$	—	$	—	$	1

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:


(in millions)	December 31, 2021		Provisions		Amounts Applied		Change in Estimates		September 30, 2022

Technologies & Equipment	$	7	$	3	$	(6)	$	—	$	4
Consumables	11		7		(8)		(1)		9
All Other	—		3		(3)		—		—
Total	$	18	$	13	$	(17)	$	(1)	$	13

The associated restructuring liabilities are recorded in Accrued liabilities and Other noncurrent liabilities in the Consolidated Balance Sheets.

FINANCIAL INSTRUMENTS AND DERIVATIVES

9 Months Ended

Sep. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

FINANCIAL INSTRUMENTS AND DERIVATIVES

Derivative Instruments and Hedging Activities

The Company’s activities expose it to a variety of market risks, which primarily include the risks related to the effects of changes in foreign currency exchange rates and interest rates. These financial exposures are monitored and managed by the Company as part of its overall risk management program. The objective of this risk management program is to reduce the volatility that these market risks may have on the Company’s operating results and cash flows. The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, or assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert fixed rate debt into variable rate debt or vice versa. The Company does not hold derivative instruments for trading or speculative purposes.

The following summarizes the notional amounts of cash flow hedges, hedges of net investments, fair value hedges, and derivative instruments not designated as hedges for accounting purposes by derivative instrument type at September 30, 2022 and the notional amounts expected to mature during the next 12 months.


(in millions)	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

Cash Flow Hedges
Foreign exchange forward contracts	$	85	$	79


Total derivative instruments designated as cash flow hedges	$	85	$	79

Hedges of Net Investments
Foreign exchange forward contracts	$	157	$	78
Cross currency basis swaps	262		—
Total derivative instruments designated as hedges of net investments	$	419	$	78

Fair Value Hedges
Interest rate swaps	$	250	$	—
Foreign exchange forward contracts	128		49
Total derivative instruments designated as fair value hedges	$	378	$	49

Derivative Instruments not Designated as Hedges
Foreign exchange forward contracts	$	27	$	27
Total derivative instruments not designated as hedges	$	27	$	27

Cash Flow Hedges

Foreign Exchange Risk Management

The Company hedges select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings. The Company designates certain foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time-value component of the fair value of the derivative is reported on a straight-line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

These foreign exchange forward contracts generally have maturities up to 18 months, which is the period over which the Company is hedging exposures to variability of cash flows and the counterparties to the transactions are typically large international financial institutions.

Interest Rate Risk Management

The Company enters into interest rate swap contracts infrequently as they are only used to manage interest rate risk on long-term debt instruments and not for speculative purposes. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

On May 26, 2020, the Company paid $31 million to settle the $150 million notional T-Lock contract, which partially hedged the interest rate risk of the $750 million senior unsecured notes. This loss is amortized over the ten-year life of the notes. As of September 30, 2022 and December 31, 2021, $23 million and $25 million, respectively, of this loss is remaining to be amortized from AOCI in future periods.

AOCI Release

Overall, the derivatives designated as cash flow hedges are considered to be highly effective for accounting purposes. At September 30, 2022, the Company expects to reclassify an immaterial amount of deferred net losses on cash flow hedges recorded in AOCI in the Consolidated Statements of Operations during the next 12 months. For the rollforward of derivative instruments designated as cash flow hedges in AOCI see Note 4, Comprehensive Income (Loss).

Hedges of Net Investments in Foreign Operations

The Company has significant investments in foreign subsidiaries. The net assets of these subsidiaries are exposed to volatility in currency exchange rates. The Company employs both derivative and non-derivative financial instruments to hedge a portion of this exposure. The derivative instruments consist of foreign exchange forward contracts and cross-currency basis swaps. The non-derivative instruments consist of foreign currency denominated debt held at the parent company level. Translation gains and losses related to the net assets of the foreign subsidiaries are offset by gains and losses in the aforementioned instruments, which are designated as hedges of net investments and are included in AOCI. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in investing activities in the Consolidated Statements of Cash Flows except for derivative instruments that include an other-than-insignificant financing element, for which all cash flows are classified as financing activities in the Consolidated Statements of Cash Flows.

The fair value of the foreign exchange forward contracts and cross-currency basis swaps is the estimated amount the Company would receive or pay at the reporting date, taking into account the effective interest rates, cross-currency swap basis rates and foreign exchange rates. The effective portion of the change in the value of these derivatives is recorded in AOCI, net of tax effects.

On July 2, 2021, the Company entered into a cross currency basis swap totaling a notional amount of $300 million which matures on June 3, 2030. The cross currency basis swap is designated as a hedge of net investments. This contract effectively converts a portion of the $750 million bond coupon from 3.3% to 1.7%.

On May 25, 2021, the Company re-established its euro net investment hedge portfolio by entering into eight foreign exchange forward contracts, each with a notional amount of 10 million euro. The original contracts have quarterly maturity dates through March 2023. The Company enters into additional foreign exchange contracts as individual contracts within the portfolio mature. As of September 30, 2022, the euro net investment hedge portfolio has an aggregate notional value of 160 million euro with maturity dates through September 2024.

Fair Value Hedges

Foreign Exchange Risk Management

The Company has intercompany loans denominated in Swedish kronor that are exposed to volatility in currency exchange rates. The Company employs derivative financial instruments to hedge these exposures. The Company accounts for these designated foreign exchange forward contracts as fair value hedges. The Company measures the effectiveness of fair value hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be recorded in the Consolidated Statements of Operations. The time-value component of the fair value of the derivative is reported on a straight-line basis in Other expense (income), net in the Consolidated Statements of Operations in the applicable period. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows.

On January 6, 2021 the Company entered into foreign exchange forward contracts with a notional value of 1.3 billion Swedish kroner as a result of an increase in intercompany loans denominated in Swedish kronor. The foreign exchange forwards are designated as fair value hedges.

Interest Rate Risk Management

On July 1, 2021, the Company entered into variable interest rate swaps with a notional amount of $250 million, which effectively convert a portion of the underlying fixed rate of 3.3% on the $750 million Senior Notes due June 2030 to a variable interest rate. Of the $250 million notional amount, $100 million has a term of five-years maturing on June 1, 2026 and $150 million has a term of nine years maturing on March 1, 2030.

Derivative Instruments Not Designated as Hedges

The Company enters into derivative instruments with the intent to partially mitigate the foreign exchange revaluation risk associated with recorded assets and liabilities that are denominated in a non-functional currency. The Company primarily uses foreign exchange forward contracts to hedge these risks. The gains and losses on these derivative transactions offset the gains and losses generated by the revaluation of the underlying non-functional currency balances and are recorded in Other expense (income), net in the Consolidated Statements of Operations. Any cash flows associated with the foreign exchange forward contracts and interest rate swaps not designated as hedges are included in operating activities in the Consolidated Statements of Cash Flows.

Gains and (losses) recorded in the Company’s Consolidated Statements of Operations related to the economic hedges not designated as hedges for the three and nine months ended September 30, 2022 and 2021 were not significant.

Derivative Instrument Activity

The amount of gains and losses recorded in the Company's Consolidated Balance Sheets and Consolidated Statements of Operations related to all derivative instruments for the three months ended September 30, 2022 and 2021 were as follows:


	Three Months Ended September 30, 2022
(in millions)	Gain (Loss) recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	3	Cost of products sold	$	1	$	—
Interest rate swaps	—		Interest expense, net	—		—


Total for cash flow hedging	$	3		$	1	$	—

Hedges of Net Investments
Cross currency basis swaps	$	18	Interest expense, net	$	—	$	2

Foreign exchange forward contracts	11		Other expense (income), net	—		—

Total for net investment hedging	$	29		$	—	$	2

Fair Value Hedges
Interest rate swaps	$	—	Interest expense, net	$	—	$	(1)
Foreign exchange forward contracts	(1)		Other expense (income), net	—		13

Total for fair value hedging	$	(1)		$	—	$	12


	Three Months Ended September 30, 2021
(in millions)	Gain (Loss) Recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	6	Cost of products sold	$	(2)	$	—
Interest rate swaps	—		Interest expense, net	(1)		—


Total for cash flow hedging	$	6		$	(3)	$	—

Hedges of Net Investments
Cross currency basis swaps	$	(1)	Interest expense, net	$	—	$	1

Foreign exchange forward contracts	4		Other expense (income), net	—		—

Total for net investment hedging	$	3		$	—	$	1

Fair Value Hedges
Foreign exchange forward contracts	$	—	Interest expense, net	$	—	$	6
Interest rate swaps	—		Cost of products sold	—		1
Total for fair value hedging	$	—		$	—	$	7

The amount of gains and losses recorded in the Company's Consolidated Balance Sheets and Consolidated Statements of Operations related to all derivative instruments for the nine months ended September 30, 2022 and 2021 were as follows:



	Nine Months Ended September 30, 2022
(in millions)	Gain (Loss) recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	3	Cost of products sold	$	3	$	—
Interest rate swaps	—		Interest expense, net	(2)		—


Total for cash flow hedging	$	3		$	1	$	—

Hedges of Net Investments
Cross currency basis swaps	$	47	Interest expense, net	$	—	$	4

Foreign exchange forward contracts	24		Other expense (income), net	—		1

Total for net investment hedging	$	71		$	—	$	5

Fair Value Hedges
Interest rate swaps	$	—	Interest expense, net	$	—	$	—
Foreign exchange forward contracts	(2)		Other expense (income), net	—		37

Total for fair value hedging	$	(2)		$	—	$	37



	Nine Months Ended September 30, 2021
(in millions)	Gain (Loss) recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	3	Cost of products sold	$	(4)	$	1
Interest rate swaps	—		Interest expense, net	(4)		—


Total for cash flow hedging	$	3		$	(8)	$	1

Hedges of Net Investments
Cross currency basis swaps	$	6	Interest expense, net	$	—	$	5

Foreign exchange forward contracts	7		Other expense (income), net	—		—

Total for net investment hedging	$	13		$	—	$	5

Fair Value Hedges
Interest rate swaps	$	—	Interest expense, net	$	—	$	1
Foreign exchange forward contracts	—		Other expense (income), net	—		18
Total for fair value hedging	$	—		$	—	$	19

Consolidated Balance Sheets Location of Derivative Fair Values

The fair value and the location of the Company's derivatives in the Consolidated Balance Sheets were as follows:


	September 30, 2022
(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:
Foreign exchange forward contracts	$	37	$	29	$	2	$	3
Interest rate swaps	—		—		9		27
Cross currency basis swaps	3		40		—		—
Total	$	40	$	69	$	11	$	30

Not Designated as Hedges:
Foreign exchange forward contracts	$	4	$	—	$	3	$	—
Total	$	4	$	—	$	3	$	—

	December 31, 2021
(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:
Foreign exchange forward contracts	$	18	$	11	$	2	$	1
Interest rate swaps	5		—		—		9
Cross currency basis swaps	4		—		—		7
Total	$	27	$	11	$	2	$	17

Not Designated as Hedges:
Foreign exchange forward contracts	$	1	$	—	$	1	$	—
Total	$	1	$	—	$	1	$	—

Balance Sheet Offsetting

Substantially all of the Company’s derivative contracts are subject to netting arrangements; whereby the right to offset occurs in the event of default or termination in accordance with the terms of the arrangements with the counterparty. While these contracts contain the enforceable right to offset through netting arrangements with the same counterparty, the Company elects to present them on a gross basis in the Consolidated Balance Sheets.

Offsetting of financial assets and liabilities under netting arrangements at September 30, 2022 were as follows:


							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	70	$	—	$	70	$	(6)	$	—	$	64


Cross currency basis swaps	43		—		43		(17)		—		26

Total assets	$	113	$	—	$	113	$	(23)	$	—	$	90

Liabilities
Foreign exchange forward contracts	$	8	$	—	$	8	$	(8)	$	—	$	—

Interest rate swaps	36		—		36		(15)		—		21


Total liabilities	$	44	$	—	$	44	$	(23)	$	—	$	21

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2021 were as follows:



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	31	$	—	$	31	$	(9)	$	—	$	22



Total assets	$	31	$	—	$	31	$	(9)	$	—	$	22

Liabilities
Foreign exchange forward contracts	$	4	$	—	$	4	$	(4)	$	—	$	—

Interest rate swaps	4		—		4		(2)		—		2
Cross currency basis swaps	4		—		4		(3)		—		1

Total liabilities	$	12	$	—	$	12	$	(9)	$	—	$	3

FAIR VALUE MEASUREMENT

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENT

The estimated fair value and carrying value of the Company's total debt, including current portion, was $1,794 million and $1,983 million, respectively, at September 30, 2022. At December 31, 2021, the estimated fair value and carrying value were $2,239 million and $2,095 million, respectively. The fair value of long-term debt is based on recent trade information in the financial markets of the Company’s public debt or is determined by discounting future cash flows using interest rates available at September 30, 2022 and December 31, 2021 to companies with similar credit ratings for issues with similar terms and maturities. It is considered a Level 2 fair value measurement for disclosure purposes.

Assets and liabilities measured at fair value on a recurring basis

The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows:



	September 30, 2022
(in millions)	Total		Level 1		Level 2		Level 3

Assets



Cross currency basis swaps	$	43	$	—	$	43	$	—
Foreign exchange forward contracts	70		—		70		—
Long-term debt	36		—		36		—
Total assets	$	149	$	—	$	149	$	—

Liabilities
Interest rate swaps	$	36	$	—	$	36	$	—


Foreign exchange forward contracts	8		—		8		—

Contingent considerations on acquisitions	4		—		—		4
Total liabilities	$	48	$	—	$	44	$	4



	December 31, 2021
(in millions)	Total		Level 1		Level 2		Level 3

Assets

Interest rate swaps	$	5	$	—	$	5	$	—

Long-term debt	4		—		4		—
Cross currency basis swaps	4		—		4		—
Foreign exchange forward contracts	30		—		30		—

Total assets	$	43	$	—	$	43	$	—

Liabilities
Interest rate swaps	$	9	$	—	$	9	$	—

Cross currency basis swaps	7		—		7		—
Foreign exchange forward contracts	4		—		4		—

Contingent considerations on acquisitions	10		—		—		10

Total liabilities	$	30	$	—	$	20	$	10

Derivative valuations are based on observable inputs to the valuation model including interest rates, foreign currency exchange rates, and credit risks. The Company utilizes interest rate swaps and foreign exchange forward contracts that are considered cash flow hedges. In addition, the Company at times employs certain cross currency basis swaps and forward exchange contracts that are considered hedges of net investment in foreign operations.

There have been no transfers between fair value measurement levels during the nine months ended September 30, 2022.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Uncertainties in Income Taxes The Company recognizes the impact of a tax position in the interim consolidated financial statements if that position is "more likely than not" of being sustained on audit based on the technical merits of the position. Under ASC 740-10, the Company provides for uncertain tax positions and the related interest expense by adjusting unrecognized tax benefits and accrued interest accordingly. The Company recognizes potential interest and penalties related to unrecognized tax benefits in income tax expense. The Company files income tax returns in multiple jurisdictions based on its operations, some of which are under examination by taxing authorities. Certain amounts of unrecognized tax benefits may increase or decrease within twelve months of the reporting date of the Company’s consolidated financial statements, primarily due to the completion of ongoing income tax examinations. Final settlement and resolution of outstanding tax matters in various jurisdictions during the next 12 months are not expected to be significant. Expiration of statutes of limitation in various jurisdictions during the next twelve months could include unrecognized tax benefits of approximately $1 million that, if recognized, would affect the effective income tax rate. Other Tax Matters The impact of discrete items is separately recognized in the quarter in which they occur. During the three and nine months ended September 30, 2022, changes in tax expense for discrete tax matters was $6 million and $7 million, respectively, which are primarily composed of changes arising from income tax filings in certain jurisdictions, offset by uncertain tax positions and related interest expense. The overall tax benefit as compared to the tax expense in prior period is driven primarily by the impairment of certain goodwill and indefinite-lived intangibles. The tax benefit attributed to the impact of the impairments is $183 million. Refer to Note 14, Goodwill and Intangible Assets in Item 1 of this Form 10-Q for further discussion of the impairments. During the three and nine months ended September 30, 2021, the Company recorded $4 million and $11 million, respectively, of tax expense for discrete tax matters. U.S. Federal Legislative Changes On August 16, 2022, the U.S. federal government enacted the Inflation Reduction Act of 2022. The bill includes numerous tax provisions, including a 15% corporate minimum tax as well as a 1% excise tax on share repurchases. The Company continues to evaluate the impact of this law on our operations; at this point, the legislation is not expected to have a material impact on consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

FINANCING ARRANGEMENTS	9 Months Ended
FINANCING ARRANGEMENTS	Sep. 30, 2022
Debt Disclosure [Abstract]
FINANCING ARRANGEMENTS	FINANCING ARRANGEMENTS At September 30, 2022, the Company had $503 million of borrowing available under lines of credit, including lines available under its short-term arrangements and revolving credit facility. The Company has a $500 million commercial paper program. The Company had outstanding borrowings of $224 million and $170 million under the commercial paper facility at September 30, 2022 and December 31, 2021, respectively. The Company also has a $700 million multi-currency revolving credit facility which serves as a back-stop credit facility for the Company's commercial paper program. At September 30, 2022 and December 31, 2021, there were no outstanding borrowings under the multi-currency revolving credit facility. The Company also has access to $48 million in uncommitted short-term financing under lines of credit from various financial institutions, the availability of which is reduced by other short-term borrowings of $21 million. At September 30, 2022, the weighted-average interest rate for short-term debt was 4.0%. The Company’s revolving credit facility, term loans and senior notes contain certain affirmative and negative debt covenants relating to the Company's operations and financial condition. At September 30, 2022, the Company was in compliance with all debt covenants. As a result of the Company’s failure to file its unaudited financial statements for the fiscal quarters ended March 31, 2022 and June 30, 2022 by the reporting deadlines, the Company obtained the consents of the requisite lenders and noteholders of its outstanding indebtedness to extend the time period for delivery of such unaudited financial statements until November 14, 2022. Those financial statements were delivered on November 9, 2022 and therefore, the Company has not suffered an event of default as a result of the delayed filings.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

The Company assesses both goodwill and indefinite-lived intangible assets for impairment annually as of April 1 or more frequently if events or changes in circumstances indicate the asset might be impaired. In preparing its financial statements for the quarter ended September 30, 2022, the Company identified indicators of a "more likely than not" impairment related to its Digital Dental Group and Equipment & Instruments reporting units, included within the Technologies & Equipment segment. The Company has experienced adverse macroeconomic factors as a result of weakened global demand, higher cost of capital, unfavorable foreign currency impacts, and increased raw material, supply chain and service costs, which are contributing to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows.

The fair values of the two reporting units above were computed using a discounted cash flow model with inputs developed using both internal and market-based data. The Company's significant assumptions in the discounted cash flow model included, but were not limited to, the weighted average cost of capital, revenue growth rates (including perpetual growth rates), and operating margin percentages of the reporting unit's business. As a result, the Company recorded a pre-tax goodwill impairment charge related to the Digital Dental Group and Equipment & Instruments reporting units within the Technologies & Equipment segment of $1,100 million and $87 million, respectively.

The timing of this impairment charge in the third quarter was the result of current macroeconomic conditions, including the rising interest rate environment and broad declines in equity valuations. Since the second quarter, core underlying market interest rates, which serve as the basis for the discount rate assumptions in our impairment models, rose by approximately 200 basis points. Further, earnings forecasts were reduced for several reporting units as these forecasts were impacted by ongoing macroeconomic forces. Global demand has weakened for certain products in the third quarter as inflationary pressures impacted the discretionary spending behavior of our customers, which has introduced new competitive challenges. Additionally, raw materials, supply chain, and service costs have all increased due to changes in our business model and broad inflationary trends.

At September 30, 2022, the remaining goodwill related to the Digital Dental Group and Equipment & Instruments reporting units was $234 million and $192 million, respectively. As the fair value of these reporting units approximate carrying value as of September 30, 2022, any further decline in key assumptions could result in additional impairment in future periods. Based on quantitative analysis performed for the other three reporting units within the Technologies & Equipment and Consumables segments, the Company believes there is no indication that the carrying value "more likely than not" exceeds the fair value in each case as of September 30, 2022; however, any further deterioration in key assumptions could result in impairment charges in the future.

For the Company's reporting units that were not impaired, the Company applied a hypothetical sensitivity analysis by increasing the discount rate of these reporting units by 100 basis points and, in a separate test, reducing by 10% the fair value of those reporting units. If discount rates were hypothetically increased by 100 basis points at September 30, 2022, one reporting unit within the Technologies & Equipment segment would have an estimated fair value less than 10% in excess of its carrying value. Goodwill associated with this reporting unit was $1,068 million at September 30, 2022.

In preparing the financial statements for the quarter ended September 30, 2022, in conjunction with the goodwill impairment, the Company tested the intangible assets related to the businesses within the Digital Dental Group and Equipment & Instruments reporting units within the Technologies & Equipment segment for impairment. The Company also identified an indicator of impairment for indefinite-lived intangible assets within the Consumables reporting unit within the Consumables segment. Intangible assets were evaluated for impairment using an income approach, specifically a relief from royalty method, or using a qualitative assessment. The Company's significant assumptions in the relief from royalty method included, but were not limited to, revenue growth rates (including perpetual growth rates), royalty rates, and discount rates. As a result, the Company recorded an impairment charge of $66 million, $26 million and $2 million for the Digital Dental Group, Equipment & Instruments and Consumables reporting units, respectively, for its indefinite-lived intangible assets for the three months ended September 30, 2022. The impairment charge was primarily driven by macroeconomic factors such as higher cost of capital, cost inflation, unfavorable foreign currency impacts, and increased supply chain costs, which are contributing to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows. This charge was recorded in Intangible asset impairment and other costs in the Consolidated Statements of Operations. As the fair value of these indefinite-lived intangible assets approximate carrying value as of September 30, 2022, any further decline in key assumptions could result in additional impairment in future periods. Based on qualitative assessments performed on the indefinite-lived intangible assets related to the businesses in the two other reporting units within the Technologies & Equipment segment, the Company believes there is no indication that the carrying value "more likely than not" exceeds the fair value of these intangible assets in each case as of September 30, 2022; however, any further deterioration in key assumptions could result in impairment charges in the future.

For the Company’s indefinite-lived intangible assets that were not impaired, the Company applied a hypothetical sensitivity analysis. If the fair value of each of these indefinite-lived intangibles assets had been hypothetically reduced by 10% or the discount rate had been hypothetically increased by 100 basis points as of September 30, 2022, the fair value of certain indefinite-lived intangible assets within the Technologies & Equipment and Consumables segments would be less than book value and are considered at-risk based on the sensitivity analysis. The carrying value of these indefinite-lived intangibles within the Technologies & Equipment and Consumables segments was $43 million and $30 million, respectively, at September 30, 2022.

Any deviation in actual financial results compared to the forecasted financial results or valuation assumptions used in the annual or interim tests, a decline in equity valuations, increases in interest rates, or changes in the use of intangible assets, among other factors, could have a material adverse effect to the fair value of either the reporting units or intangible assets and could result in a future impairment charge. There can be no assurance that the Company’s future asset impairment testing will not result in a material charge to earnings.

A reconciliation of changes in the Company’s goodwill by reportable segment were as follows:


(in millions)	Technologies & Equipment		Consumables		Total

Balance at December 31, 2021
Goodwill	$	5,989	$	880	$	6,869
Accumulated impairment losses	(2,893)		—		(2,893)
Goodwill, net	$	3,096	$	880	$	3,976


Impairment	(1,187)		—		(1,187)
Translation and other	(170)		(35)		(205)

Balance at September 30, 2022
Goodwill	$	5,819	$	845	$	6,664
Accumulated impairment losses	(4,080)		—		(4,080)
Goodwill, net	$	1,739	$	845	$	2,584

Identifiable definite-lived and indefinite-lived intangible assets were as follows:


	September 30, 2022						December 31, 2021
(in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount

Developed technology and patents	$	1,569	$	(764)	$	805	$	1,729	$	(762)	$	967
Tradenames and trademarks	269		(90)		179		269		(79)		190
Licensing agreements	31		(26)		5		36		(32)		4
Customer relationships	1,005		(553)		452		1,091		(545)		546
Total definite-lived	$	2,874	$	(1,433)	$	1,441	$	3,125	$	(1,418)	$	1,707

Indefinite-lived tradenames and trademarks	$	426	$	—	$	426	$	598	$	—	$	598
In-process R&D (a)	8		—		8		14		—		14
Total indefinite-lived	$	434	$	—	$	434	$	612	$	—	$	612

Total identifiable intangible assets	$	3,308	$	(1,433)	$	1,875	$	3,737	$	(1,418)	$	2,319

(a) Intangible assets acquired in a business combination that are in-process and used in research and development ("R&D") activities are considered indefinite-lived until the completion or abandonment of the R&D efforts. The useful life and amortization of those assets will be determined once the R&D efforts are completed. During the third quarter of 2022, the completion of certain R&D activities occurred, resulting in the reclassification of $5 million of in-process R&D to in-service assets with a definite life.

During the second quarter of 2021, the Company purchased certain developed technology rights for an initial payment of $3 million. The purchase consideration also includes minimum guaranteed contingent payments of $17 million to be made upon reaching certain regulatory and commercial milestones. The contingent payments are not yet considered probable of payment as of September 30, 2022.

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

Contingencies

On January 25, 2018, Futuredontics, Inc., a former wholly-owned subsidiary of the Company, received service of a purported class action lawsuit brought by Henry Olivares and other similarly situated individuals in the Superior Court of the State of California for the County of Los Angeles. In January 2019, an amended complaint was filed adding another named plaintiff, Rachael Clarke, and various claims. The plaintiff class alleges several violations of the California wage and hours laws, including, but not limited to, failure to provide rest and meal breaks and the failure to pay overtime. The parties have engaged in written and other discovery. On February 5, 2019, Plaintiff Calethia Holt (represented by the same counsel as Mr. Olivares and Ms. Clarke) filed a separate representative action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. On April 5, 2019, Plaintiff Kendra Cato filed a similar action in Los Angeles Superior Court alleging a single violation of the Private Attorneys’ General Act that is based on the same underlying claims as the Olivares/Clarke lawsuit. The Company has agreed to resolve all three actions (Olivares, Holt, and Cato). The court in Cato approved the settlement in that case, the settlement payment has been made, and the court dismissed the lawsuit. The parties to Olivares and Holt are in the process of seeking court approval of that settlement. The expected settlement amount, which is immaterial to the financial statements, has been recorded as an accrued liability within the Company's consolidated balance sheet as of September 30, 2022.

On June 7, 2018, and August 9, 2018, two putative class action suits were filed, and later consolidated, in the Supreme Court of the State of New York, County of New York claiming that the Company and certain individual defendants, violated U.S. securities laws (the "State Court Action") by making material misrepresentations and omitting required information in the December 4, 2015 registration statement filed with the SEC in connection with the 2016 merger of Sirona Dental Systems Inc. ("Sirona") with DENTSPLY International Inc. (the "Merger"). The amended complaint alleges that the defendants failed to disclose, among other things, that a distributor had purchased excessive inventory of legacy Sirona products and that three distributors of the Company's products had been engaging in anticompetitive conduct. The plaintiffs seek to recover damages on behalf of a class of former Sirona shareholders who exchanged their shares for shares of the Company's stock in the Merger. On September 26, 2019, the Court granted the Company's motion to dismiss all claims and a judgement dismissing the case was subsequently entered. On February 4, 2020, the Court denied plaintiffs' post-judgement motion to vacate or modify the judgement and to grant them leave to amend their complaint. The plaintiffs appealed the dismissal and the denial of the post-judgement motion to the Supreme Court of the State of New York, Appellate Division, First Department, and the Company cross-appealed select rulings in the Court's decision dismissing the action. The plaintiffs' appeals and the Company's cross-appeal were consolidated and argued on January 12, 2021. On February 2, 2021, the Appellate Division issued its decision upholding the dismissal of the State Court Action with prejudice on statute of limitations grounds. The Plaintiffs did not appeal the Appellate Division decision.

On December 19, 2018, a related putative class action was filed in the U.S. District Court for the Eastern District of New York against the Company and certain individual defendants (the "Federal Class Action"). The plaintiff makes similar allegations and asserts the same claims as those asserted in the State Court Action. In addition, the plaintiff alleges that the defendants violated U.S. securities laws by making false and misleading statements in quarterly and annual reports and other public statements between February 20, 2014, and August 7, 2018. The plaintiff asserts claims on behalf of a putative class consisting of (a) all purchasers of the Company's stock during the period February 20, 2014 through August 7, 2018 and (b) former shareholders of Sirona who exchanged their shares of Sirona stock for shares of the Company's stock in the Merger. The Company moved to dismiss the amended complaint on August 15, 2019. The plaintiff filed its second amended complaint on January 22, 2021, and the Company filed a motion to dismiss the second amended complaint on March 8, 2021. Briefing on the motion to dismiss was fully submitted on May 21, 2021, and that motion is currently pending before the Court.

On June 2, 2022, the Company was named as a defendant in a putative class action filed in the United States District Court for the Southern District of Ohio captioned City of Miami General Employees’ & Sanitation Employees’ Retirement Trust v. Casey, Jr. et al., No. 2:22-cv-02371 (S.D. Ohio), and on July 28, 2022, the Company was named as a defendant in a putative class action filed in the United States District Court for the Southern District of New York captioned San Antonio Fire and Police Pension Fund v. Dentsply Sirona Inc. et al., No. 1:22-cv-06339 (together, the “Securities Litigation”). The complaints in the Securities Litigation are substantially similar and both allege that, during the period June 9, 2021 through May 9, 2022, the Company, Mr. Donald M. Casey Jr., the Company’s former Chief Executive Officer, and Mr. Jorge Gomez, the Company’s former Chief Financial Officer, violated United States securities laws by, among other things, making materially false and misleading statements or omissions, including regarding the manner in which the Company recognizes revenue tied to distributor rebate and incentive programs.

No specific amounts of damages have been alleged in these lawsuits. We will continue to incur legal fees in connection with these pending cases, including expenses for the reimbursement of legal fees of present and former officers and directors under indemnification obligations. The expense of continuing to defend such litigation may be significant. We intend to defend these lawsuits vigorously, but there can be no assurance that we will be successful in any defense. If any of the lawsuits are decided adversely, we may be liable for significant damages directly or under our indemnification obligations, which could adversely affect our business, results of operations and cash flows. At this stage, we are unable to assess whether any material loss or adverse effect is reasonably possible as a result of these lawsuits or estimate the range of any potential loss.

As a result of an audit by the IRS for fiscal years 2012 through 2013, on February 11, 2019, the IRS issued to the Company a “30-day letter” and a Revenue Agent’s Report (“RAR”), relating to the Company’s worthless stock deduction in 2013 in the amount of $546 million. The RAR disallows the deduction and, after adjusting the Company’s net operating loss carryforward, asserts that the Company is entitled to a refund of $5 million for 2012, has no tax liability for 2013, and owes a deficiency of $17 million in tax for 2014, excluding interest. In accordance with ASC 740, the Company recorded the tax benefit associated with the worthless stock deduction in the Company’s 2012 financial statements. In March 2019, the Company submitted a formal protest disputing on multiple grounds the proposed taxes. The Company and its advisors discussed its position with the IRS Appeals Office Team on October 28, 2020 and, on November 13, 2020, submitted a supplemental response to questions raised by the Appeals Team. The Company’s position continues to be reviewed by the IRS Appeals Office team. The Company believes the IRS' position is without merit and believes that it is more likely-than-not the Company’s position will be sustained upon further review by the IRS Appeals Office Team. The Company has not accrued a liability relating to the proposed tax adjustments. However, the outcome of this dispute involves a number of uncertainties, including those inherent in the valuation of various assets at the time of the worthless stock deduction, and those relating to the application of the Internal Revenue Code and other federal income tax authorities and judicial precedent. Accordingly, there can be no assurance that the dispute with the IRS will be resolved favorably. If determined adversely, the dispute would result in a current period charge to earnings and could have a material adverse effect in the consolidated results of operations, financial position, and liquidity of the Company.

The Swedish Tax Agency has disallowed certain of the Company’s interest expense deductions for the tax years from 2013 to 2018. If such interest expense deductions were disallowed, the Company would be subject to an additional $36 million in tax expense. The Company has appealed the disallowance to the Swedish Administrative Court. With respect to such deductions taken in the tax years from 2013 to 2014, the Court ruled against the Company on July 5, 2017. On August 7, 2017, the Company appealed the unfavorable decision of the Swedish Administrative Court. On November 5, 2018, the Company delivered its final argument to the Administrative Court of Appeals at a hearing. The European Union Commission has taken the view that Sweden’s interest deduction limitation rules are incompatible with European Union law and supporting legal opinions, and therefore the Company has not paid the tax or made provision in its financial statements for such potential expense. This view has now been confirmed by the European Union Court of Justice in a preliminary ruling requested by the Swedish Supreme Administrative Court. Subsequently, the Swedish Tax Authority has conceded in pending court proceedings that the Company should be granted further interest expense deductions, but still claims that interest expense deductions incurring a maximum additional tax expense of $7 million should be disallowed on grounds not relating to European Union law.

The Company intends to vigorously defend its positions and pursue related appeals in the above-described pending matters.

In addition to the matters disclosed above, the Company is, from time to time, subject to a variety of litigation and similar proceedings incidental to its business. These legal matters primarily involve claims for damages arising out of the use of the Company’s products and services and claims relating to intellectual property matters including patent infringement, employment matters, tax matters, commercial disputes, competition and sales and trading practices, personal injury, and insurance coverage. The Company may also become subject to lawsuits as a result of past or future acquisitions or as a result of liabilities retained from, or representations, warranties or indemnities provided in connection with, divested businesses. Some of these lawsuits may include claims for punitive and consequential, as well as compensatory damages. Except as otherwise noted, the Company generally cannot predict what the eventual outcome of the above-described pending matters will be, what the timing of the ultimate resolution of these matters will be, or what the eventual loss, fines or penalties related to each pending matter may be. Based upon the Company’s experience, current information, and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its consolidated results of operations, financial position, or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations, or liquidity.

While the Company maintains general, product, property, workers’ compensation, automobile, cargo, aviation, crime, fiduciary and directors’ and officers’ liability insurance up to certain limits that cover certain of these claims, this insurance may be insufficient or unavailable to cover such losses. In addition, while the Company believes it is entitled to indemnification from third parties for some of these claims, these rights may also be insufficient or unavailable to cover such losses.

Commitments

Purchase Commitments

The Company has certain non-cancelable future commitments primarily related to long-term supply contracts for key components and raw materials. At September 30, 2022, non-cancelable purchase commitments are as follows:


(in millions)


2022	$	66
2023	175
2024	77
2025	58
2026	69
Thereafter	—
Total	$	445

The above information should be read in conjunction with Part II, Item 7 “Contractual Obligations” and Part II, Item 8, Note 22 “Commitments and Contingencies” in our 2021 Form 10-K/A.

Off-Balance Sheet Arrangements

As of September 30, 2022, we had no material off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on our consolidated financial condition, results of operations, liquidity, capital expenditures or capital resources other than certain items disclosed in the sections above.

Indemnification

In the normal course of business to facilitate sale of our products and services, we indemnify certain parties: customers, vendors, lessors, and other parties with respect to certain matters, including, but not limited to, services to be provided by us and intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with our directors and our executive officers that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Several of these agreements limit the time within which an indemnification claim can be made and the amount of the claim.

It is not possible to make a reasonable estimate of the maximum potential amount under these indemnification agreements due to the unique facts and circumstances involved in each particular agreement. Additionally, we have a limited history of prior indemnification claims and the payments we have made under such agreements have not had a material effect on our results of operations, cash flows or financial position. As of September 30, 2022, we did not have any material indemnification claims that were probable or reasonably possible. However, to the extent that valid indemnification claims arise in the future, future payments by us could be significant and could have a material adverse effect on our results of operations or cash flows in a particular period.

SIGNIFICANT ACCOUNTING POLICIES AND RESTATEMENT (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the U.S. Securities and Exchange Commission (“SEC”). In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair statement of the results for interim periods have been included. Results for interim periods should not be considered indicative of results for a full year. These financial statements and related notes contain the accounts of DENTSPLY SIRONA Inc. and subsidiaries (“Dentsply Sirona” or the “Company”) on a consolidated basis and should be read in conjunction with the consolidated financial statements and notes included in the Company’s most recent Form 10-K/A for the year ended December 31, 2021, as amended and filed on November 7, 2022. Recently Concluded Investigation As previously disclosed, the Audit and Finance Committee of the Company's Board of Directors (the "Audit and Finance Committee"), assisted by independent legal counsel and forensic accountants, commenced an internal investigation in March 2022 of allegations regarding certain financial reporting matters submitted by current and former employees of the Company. The investigation was conducted in two components, one pertaining to allegations regarding the Company’s use of incentives to sell products to certain distributors in North America in the third and fourth quarters of 2021 (the "North American Investigation") and another to analyze the increase in returns of products in China during the fourth quarter of 2021 identified by the Company (the "China Investigation"). In the North America Investigation, the Audit and Finance Committee concluded that there was no evidence of intentional wrongdoing or fraud. The Audit and Finance Committee found that certain former members of senior management, including the Company's former Chief Executive Officer and former Chief Financial Officer, violated provisions of the Company's Code of Ethics and Business Conduct. In addition, these former members of senior management did not maintain and promote an appropriate control environment focused on compliance in areas of the Company’s business, nor did they sufficiently promote, monitor or enforce adherence to the Code of Ethics and Business Conduct. The North America Investigation found that certain former members of senior management, including the former Chief Executive Officer and the former Chief Financial Officer created a culture where employees did not feel comfortable raising concerns without fear of retaliation. In addition, the North America Investigation substantiated certain allegations regarding inappropriate tone at the top by the former Chief Executive Officer and the former Chief Financial Officer. Based on the China Investigation, the Audit and Finance Committee concluded that members of the Company's local commercial team in China, as well as the head of the Company's Asia-Pacific commercial organization, committed intentional wrongdoing by failing to provide requested information to the Company's local accounting team, by obstructing the work of the accounting team and by lacking truthfulness in providing information to the Company and to the Audit and Finance Committee as part of the China Investigation. The China Investigation also determined that these actions by the certain members of the Company's local commercial team in China, as well as the former Chief Financial Officer and the head of the Company's Asia-Pacific commercial organization, violated the Company's Code of Ethics and Business Conduct. On October 29, 2022, the Audit and Finance Committee determined that its investigation was complete.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of Net sales and expense during the reporting period. Actual results could differ materially from those estimates. Specifically, for the three months ended September 30, 2022, some of these estimates and assumptions continue to be based on an ongoing evaluation of expected future impacts from the COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly have a negative material impact on the Company's financial condition, liquidity, or results of operations in future periods is highly uncertain and difficult to predict. More specifically, although demand for the Company’s products has largely recovered from the impact of rigorous preventive measures implemented at the outset of the pandemic, it continues to be affected by social distancing guidelines, dental practice safety protocols which reduce patient traffic, and some lingering patient reluctance to seek dental care. Also, impacts from the pandemic continue to be experienced in the form of shortages for specific materials such as electronic components, higher related transportation costs, and labor shortages. Throughout 2022, the Company has continued to experience supply chain constraints, which has impacted its ability to timely produce and deliver certain products, and has also resulted in increases in shipping rates. In the third quarter the Company has been further impacted by deteriorating macroeconomic conditions more generally, including rising global interest rates and inflationary pressures which have raised the price of inputs, impacted the discretionary spending behavior of our customers, and introduced new competitive challenges. To address these issues, the Company has taken steps to mitigate the impact of these trends, including continued emphasis on cost reduction and supply chain efficiencies. However, uncertainties remain regarding how long these impacts will continue or whether future variants of the virus may have an adverse impact in affected markets.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In March 2020, the Financial Accounting Standards Board ("FASB") issued ASU No. 2020-04 "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting", which was subsequently amended by ASU No. 2021-01 "Reference Rate Reform (Topic 848): Scope" in January 2021. The new standard provides optional expedients and exceptions to contracts, hedging relationships, and other transactions that reference the London Interbank Offer Rate ("LIBOR") or another rate expected to be discontinued due to the reference rate reform. The amendments in this standard were effective upon issuance and generally can be applied to contract modifications made or evaluated through December 31, 2022. The Company does not expect this standard to have a material impact on its consolidated financial statements and related disclosures. In October 2021, the FASB issued ASU No. 2021-08, "Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (Topic 805)", which requires contract assets and liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. The current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value differs from the current approach. This standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently assessing the impact of this standard on its consolidated financial statements and related disclosures.
Revenue	Revenues are measured as the amount of consideration the Company expects to receive in exchange for transferring goods or providing services.
Inventory	Inventories are stated at the lower of cost and net realizable value.
Foreign Exchange Risk Management	Foreign Exchange Risk Management The Company hedges select anticipated foreign currency cash flows to reduce volatility in both cash flows and reported earnings. The Company designates certain foreign exchange forward contracts as cash flow hedges. As a result, the Company records the fair value of the contracts primarily through AOCI based on the assessed effectiveness of the foreign exchange forward contracts. The Company measures the effectiveness of cash flow hedges of anticipated transactions on a spot-to-spot basis rather than on a forward-to-forward basis. Accordingly, the spot-to-spot change in the derivative fair value will be deferred in AOCI and released and recorded in the Consolidated Statements of Operations in the same period that the hedged transaction is recorded. The time-value component of the fair value of the derivative is reported on a straight-line basis in Cost of products sold in the Consolidated Statements of Operations in the period which it is applicable. Any cash flows associated with these instruments are included in operating activities in the Consolidated Statements of Cash Flows. These foreign exchange forward contracts generally have maturities up to 18 months, which is the period over which the Company is hedging exposures to variability of cash flows and the counterparties to the transactions are typically large international financial institutions.
Income Taxes	Under ASC 740-10, the Company provides for uncertain tax positions and the related interest expense by adjusting unrecognized tax benefits and accrued interest accordingly. The Company recognizes potential interest and penalties related to unrecognized tax benefits in income tax expense.
Goodwill & Intangible Assets	The Company assesses both goodwill and indefinite-lived intangible assets for impairment annually as of April 1 or more frequently if events or changes in circumstances indicate the asset might be impaired. In preparing its financial statements for the quarter ended September 30, 2022, the Company identified indicators of a "more likely than not" impairment related to its Digital Dental Group and Equipment & Instruments reporting units, included within the Technologies & Equipment segment. The Company has experienced adverse macroeconomic factors as a result of weakened global demand, higher cost of capital, unfavorable foreign currency impacts, and increased raw material, supply chain and service costs, which are contributing to reduced forecasted revenues, lower operating margins, and reduced expectations for future cash flows.The fair values of the two reporting units above were computed using a discounted cash flow model with inputs developed using both internal and market-based data. The Company's significant assumptions in the discounted cash flow model included, but were not limited to, the weighted average cost of capital, revenue growth rates (including perpetual growth rates), and operating margin percentages of the reporting unit's business.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

REVENUE (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue

Net sales disaggregated by product category for the three and nine months ended September 30, 2022 and 2021 were as follows:


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Equipment & Instruments	$	163	$	176	$	498	$	523
CAD/CAM	116		147		351		403
Orthodontics	76		63		220		212
Implants	135		150		439		461
Healthcare	66		76		208		225
Technology & Equipment segment revenue	$	556	$	612	$	1,716	$	1,824

Endodontic & Restorative	$	282	$	313	$	887	$	953
Other Consumables	109		115		336		351
Consumables segment revenue	$	391	$	428	$	1,223	$	1,304

Total net sales	$	947	$	1,040	$	2,939	$	3,128

Revenue from External Customers by Geographic Areas

Net sales disaggregated by geographic region for the three and nine months ended September 30, 2022 and 2021 were as follows:


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

United States	$	357	$	384	$	1,023	$	1,094
Europe	358		393		1,183		1,239
Rest of World	232		263		733		795

Total net sales	$	947	$	1,040	$	2,939	$	3,128

STOCK COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Based Compensation

The amounts of stock compensation expense recorded in the Company's Consolidated Statements of Operations for the three and nine months ended September 30, 2022 and 2021 were as follows:


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Cost of products sold	$	1	$	2	$	2	$	4
Selling, general, and administrative expense	12		19		43		48
Research and development expense	1		1		2		2
Total stock based compensation expense	$	14	$	22	$	47	$	54

Related deferred income tax benefit	$	1	$	2	$	4	$	6

COMPREHENSIVE INCOME (LOSS) (Tables)

9 Months Ended

Sep. 30, 2022

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in Accumulated other comprehensive income (loss) ("AOCI"), net of tax, by component for the nine months ended September 30, 2022 and 2021 were as follows:



(in millions)	Foreign Currency Translation Gain (Loss)		Gain (Loss) on Cash Flow Hedges		Gain (Loss) on Net Investment and Fair Value Hedges		Pension Liability Gain (Loss)		Total

Balance, net of tax, at December 31, 2021	$	(366)	$	(16)	$	(103)	$	(107)	$	(592)
Other comprehensive (loss) income before reclassifications and tax impact	(37)		3		9		—		(25)
Tax expense	(11)		—		(1)		—		(12)
Other comprehensive (loss) income, net of tax, before reclassifications	(48)		3		8		—		(37)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		(1)		—		1		—
Net (decrease) increase in other comprehensive income	(48)		2		8		1		(37)


Balance, net of tax, at March 31, 2022	$	(414)	$	(14)	$	(95)	$	(106)	$	(629)
Other comprehensive (loss) income before reclassifications and tax impact	(86)		(3)		32		—		(57)
Tax expense	(28)		—		(8)		—		(36)
Other comprehensive (loss) income, net of tax, before reclassifications	(114)		(3)		24		—		(93)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		1		—		2		3
Net (decrease) increase in other comprehensive income	(114)		(2)		24		2		(90)


Balance, net of tax, at June 30, 2022	$	(528)	$	(16)	$	(71)	$	(104)	$	(719)
Other comprehensive (loss) income before reclassifications and tax impact	(120)		3		28		—		(89)
Tax expense	(28)		(1)		(7)		—		(36)
Other comprehensive (loss) benefit, net of tax, before reclassifications	(148)		2		21		—		(125)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		(1)		—		1		—
Net (decrease) increase in other comprehensive income	(148)		1		21		1		(125)


Balance, net of tax, at September 30, 2022	$	(676)	$	(15)	$	(50)	$	(103)	$	(844)


(in millions)	Foreign Currency Translation Gain (Loss)		Gain (Loss) on Cash Flow Hedges		Gain (Loss) on Net Investment and Fair Value Hedges		Pension Liability Gain (Loss)		Total

Balance, net of tax, at December 31, 2020	$	(187)	$	(25)	$	(119)	$	(133)	$	(464)
Other comprehensive (loss) income before reclassifications and tax impact	(74)		(6)		9		3		(68)
Tax (expense) benefit	(25)		2		(2)		(1)		(26)
Other comprehensive (loss) income, net of tax, before reclassifications	(99)		(4)		7		2		(94)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		2		—		2		4
Net (decrease) increase in other comprehensive income	(99)		(2)		7		4		(90)
Balance, net of tax, at March 31, 2021	$	(286)	$	(27)	$	(112)	$	(129)	$	(554)
Other comprehensive income before reclassifications and tax impact	31		3		1		—		35
Tax benefit (expense)	6		(2)		(1)		—		3
Other comprehensive income, net of tax, before reclassifications	37		1		—		—		38
Amounts reclassified from accumulated other comprehensive income, net of tax	—		3		—		2		5
Net increase in other comprehensive income	37		4		—		2		43

Balance, net of tax, at June 30, 2021	$	(249)	$	(23)	$	(112)	$	(127)	$	(511)
Other comprehensive (loss) income before reclassifications and tax impact	(59)		6		3		—		(50)
Tax expense	(9)		(1)		(1)		—		(11)
Other comprehensive (loss) income, net of tax, before reclassifications	(68)		5		2		—		(61)
Amounts reclassified from accumulated other comprehensive income, net of tax	—		3		—		2		5
Net (decrease) increase in other comprehensive income	(68)		8		2		2		(56)
Balance, net of tax, at September 30, 2020	$	(317)	$	(15)	$	(110)	$	(125)	$	(567)

EARNINGS PER COMMON SHARE (Tables)

9 Months Ended

Sep. 30, 2022

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The computation of basic and diluted earnings per common share for the three and nine months ended September 30, 2022 and 2021 were as follows:


Basic Earnings Per Common Share	Three Months Ended				Nine Months Ended
(in millions, except per share amounts)	2022		2021		2022		2021

Net (loss) income attributable to Dentsply Sirona	$	(1,077)	$	84	$	(935)	$	292

Weighted average common shares outstanding	214.9		218.6		215.6		218.6

(Loss) earnings per common share - basic	$	(5.01)	$	0.39	$	(4.34)	$	1.34

Diluted Earnings Per Common Share	Three Months Ended				Nine Months Ended
(in millions, except per share amounts)	2022		2021		2022		2021

Net (loss) income attributable to Dentsply Sirona	$	(1,077)	$	84	$	(935)	$	292

Weighted average common shares outstanding	214.9		218.6		215.6		218.6
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards	—		1.9		—		2.1
Total weighted average diluted shares outstanding	214.9		220.5		215.6		220.7

(Loss) earnings per common share - diluted	$	(5.01)	$	0.38	$	(4.34)	$	1.32

Accelerated Share Repurchases


(in millions, except per share amounts)			Initial Delivery					Final Settlement
Agreement Date	Amount Paid		Shares Received	Price per share		Value of Shares as a % of Contract Value		Settlement Date	Total Shares Received	Average Price per Share
March 8, 2022	$	150	2.4	$	50.44	80	%	April 19, 2022	3.1	$	48.22

BUSINESS COMBINATIONS (Tables)

9 Months Ended

Sep. 30, 2022

Business Combination and Asset Acquisition [Abstract]

Schedule of Intangible Assets Acquired

Identifiable intangible assets acquired were as follows:

Weighted Average

Useful Life

(in millions, except for useful life)

Amount

(in years)

In-process R&D

Indefinite

Identifiable intangible assets acquired were as follows:

Weighted Average

Useful Life

(in millions, except for useful life)

Amount

(in years)

Developed technology

Identifiable intangible assets acquired were as follows:


			Weighted Average
			Useful Life
(in millions, except for useful life)	Amount		(in years)

Developed technology	$	66	15
In-process R&D	10		Indefinite
Total	$	76

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed

The fair values of the assets acquired and liabilities assumed in connection with the Propel Orthodontics acquisition were as follows:


(in millions)


Other current assets	$	4
Intangible assets	66
Current liabilities	(1)
Net assets acquired	69
Goodwill	63
Purchase consideration	$	132

The fair values of the assets acquired and liabilities assumed in connection with the Datum acquisition were as follows:


(in millions)

Cash and cash equivalents	$	2
Other current assets	2
Intangible assets	76
Current liabilities	(2)
Other long-term assets (liabilities), net	(14)
Net assets acquired	64
Goodwill	39
Purchase consideration	$	103

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2022

Segment Reporting [Abstract]

Third Party Net Sales

The Company’s segment information for the three and nine months ended September 30, 2022 and 2021 was as follows:

Net Sales


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Technologies & Equipment	$	556	$	612	$	1,716	$	1,824
Consumables	391		428		1,223		1,304
Total net sales	$	947	$	1,040	$	2,939	$	3,128

Segment Adjusted Operating Income


	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Technologies & Equipment	$	73	$	134	$	278	$	391
Consumables	121		123		398		426
Segment adjusted operating income	194		257		676		817

Reconciling items expense (income):
All other (a)	77		67		223		199
Goodwill impairment	1,187		—		1,187		—
Intangible asset impairment and other costs	97		3		107		11
Interest expense, net	14		14		41		43

Other expense (income), net	9		5		20		4
Amortization of intangible assets	51		56		159		167
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations	—		(1)		2		4
(Loss) income before income taxes	$	(1,241)	$	113	$	(1,063)	$	389

(a) Includes the results of unassigned Corporate headquarters costs and inter-segment eliminations.

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2022

Inventory Disclosure [Abstract]

Inventories, Net

Inventories, net were as follows:


(in millions)	September 30, 2022		December 31, 2021

Raw materials and supplies	$	142	$	139
Work-in-process	70		72
Finished goods	380		304
Inventories, net	$	592	$	515

INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS (Tables)

9 Months Ended

Sep. 30, 2022

Restructuring and Related Activities [Abstract]

Schedule of Intangible Asset Impairment and Other Costs

Intangible asset impairment and other costs for the three and nine months ended September 30, 2022 and 2021 were as follows:


Affected Line Item in the Consolidated Statements of Operations	Three Months Ended				Nine Months Ended
(in millions)	2022		2021		2022		2021

Cost of products sold	$	—	$	—	$	—	$	(3)
Selling, general, and administrative expenses	—		3		—		6
Intangible asset impairment and other costs	97		3		107		11

Total intangible asset impairment and other costs	$	97	$	6	$	107	$	14

Restructuring Accruals

The Company’s restructuring accruals at September 30, 2022 were as follows:


	Severance
(in millions)	2020 and Prior Plans		2021 Plans		2022 Plans		Total

Balance at December 31, 2021	$	5	$	9	$	—	$	14
Provisions	1		1		8		10
Amounts applied	(3)		(5)		(3)		(11)
Change in estimates	(1)		—		—		(1)
Balance at September 30, 2022	$	2	$	5	$	5	$	12


	Other Restructuring Costs
(in millions)	2020 and Prior Plans		2021 Plans		2022 Plans		Total

Balance at December 31, 2021	$	4	$	—	$	—	$	4
Provisions	1		1		1		3
Amounts applied	(4)		(1)		(1)		(6)

Balance at September 30, 2022	$	1	$	—	$	—	$	1

Cumulative Amounts for the Provisions and Adjustments and Amounts Applied for All the Plans by Segment

The cumulative amounts for the provisions and adjustments and amounts applied for all the plans by segment were as follows:


(in millions)	December 31, 2021		Provisions		Amounts Applied		Change in Estimates		September 30, 2022

Technologies & Equipment	$	7	$	3	$	(6)	$	—	$	4
Consumables	11		7		(8)		(1)		9
All Other	—		3		(3)		—		—
Total	$	18	$	13	$	(17)	$	(1)	$	13

FINANCIAL INSTRUMENTS AND DERIVATIVES (Tables)

9 Months Ended

Sep. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Notional Amounts of Outstanding Derivative Positions


(in millions)	Aggregate Notional Amount		Aggregate Notional Amount Maturing within 12 Months

Cash Flow Hedges
Foreign exchange forward contracts	$	85	$	79


Total derivative instruments designated as cash flow hedges	$	85	$	79

Hedges of Net Investments
Foreign exchange forward contracts	$	157	$	78
Cross currency basis swaps	262		—
Total derivative instruments designated as hedges of net investments	$	419	$	78

Fair Value Hedges
Interest rate swaps	$	250	$	—
Foreign exchange forward contracts	128		49
Total derivative instruments designated as fair value hedges	$	378	$	49

Derivative Instruments not Designated as Hedges
Foreign exchange forward contracts	$	27	$	27
Total derivative instruments not designated as hedges	$	27	$	27

Schedule of Derivative Instruments


	Three Months Ended September 30, 2022
(in millions)	Gain (Loss) recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	3	Cost of products sold	$	1	$	—
Interest rate swaps	—		Interest expense, net	—		—


Total for cash flow hedging	$	3		$	1	$	—

Hedges of Net Investments
Cross currency basis swaps	$	18	Interest expense, net	$	—	$	2

Foreign exchange forward contracts	11		Other expense (income), net	—		—

Total for net investment hedging	$	29		$	—	$	2

Fair Value Hedges
Interest rate swaps	$	—	Interest expense, net	$	—	$	(1)
Foreign exchange forward contracts	(1)		Other expense (income), net	—		13

Total for fair value hedging	$	(1)		$	—	$	12


	Three Months Ended September 30, 2021
(in millions)	Gain (Loss) Recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	6	Cost of products sold	$	(2)	$	—
Interest rate swaps	—		Interest expense, net	(1)		—


Total for cash flow hedging	$	6		$	(3)	$	—

Hedges of Net Investments
Cross currency basis swaps	$	(1)	Interest expense, net	$	—	$	1

Foreign exchange forward contracts	4		Other expense (income), net	—		—

Total for net investment hedging	$	3		$	—	$	1

Fair Value Hedges
Foreign exchange forward contracts	$	—	Interest expense, net	$	—	$	6
Interest rate swaps	—		Cost of products sold	—		1
Total for fair value hedging	$	—		$	—	$	7



	Nine Months Ended September 30, 2022
(in millions)	Gain (Loss) recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	3	Cost of products sold	$	3	$	—
Interest rate swaps	—		Interest expense, net	(2)		—


Total for cash flow hedging	$	3		$	1	$	—

Hedges of Net Investments
Cross currency basis swaps	$	47	Interest expense, net	$	—	$	4

Foreign exchange forward contracts	24		Other expense (income), net	—		1

Total for net investment hedging	$	71		$	—	$	5

Fair Value Hedges
Interest rate swaps	$	—	Interest expense, net	$	—	$	—
Foreign exchange forward contracts	(2)		Other expense (income), net	—		37

Total for fair value hedging	$	(2)		$	—	$	37



	Nine Months Ended September 30, 2021
(in millions)	Gain (Loss) recognized in AOCI		Consolidated Statements of Operations Location	Effective Portion Reclassified from AOCI into Income (Expense)		Recognized in Income (Expense)

Cash Flow Hedges
Foreign exchange forward contracts	$	3	Cost of products sold	$	(4)	$	1
Interest rate swaps	—		Interest expense, net	(4)		—


Total for cash flow hedging	$	3		$	(8)	$	1

Hedges of Net Investments
Cross currency basis swaps	$	6	Interest expense, net	$	—	$	5

Foreign exchange forward contracts	7		Other expense (income), net	—		—

Total for net investment hedging	$	13		$	—	$	5

Fair Value Hedges
Interest rate swaps	$	—	Interest expense, net	$	—	$	1
Foreign exchange forward contracts	—		Other expense (income), net	—		18
Total for fair value hedging	$	—		$	—	$	19

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

The fair value and the location of the Company's derivatives in the Consolidated Balance Sheets were as follows:


	September 30, 2022
(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:
Foreign exchange forward contracts	$	37	$	29	$	2	$	3
Interest rate swaps	—		—		9		27
Cross currency basis swaps	3		40		—		—
Total	$	40	$	69	$	11	$	30

Not Designated as Hedges:
Foreign exchange forward contracts	$	4	$	—	$	3	$	—
Total	$	4	$	—	$	3	$	—

	December 31, 2021
(in millions)	Prepaid Expenses and Other Current Assets		Other Noncurrent Assets		Accrued Liabilities		Other Noncurrent Liabilities

Designated as Hedges:
Foreign exchange forward contracts	$	18	$	11	$	2	$	1
Interest rate swaps	5		—		—		9
Cross currency basis swaps	4		—		—		7
Total	$	27	$	11	$	2	$	17

Not Designated as Hedges:
Foreign exchange forward contracts	$	1	$	—	$	1	$	—
Total	$	1	$	—	$	1	$	—

Offsetting Derivative Assets and Liabilities

Offsetting of financial assets and liabilities under netting arrangements at September 30, 2022 were as follows:


							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	70	$	—	$	70	$	(6)	$	—	$	64


Cross currency basis swaps	43		—		43		(17)		—		26

Total assets	$	113	$	—	$	113	$	(23)	$	—	$	90

Liabilities
Foreign exchange forward contracts	$	8	$	—	$	8	$	(8)	$	—	$	—

Interest rate swaps	36		—		36		(15)		—		21


Total liabilities	$	44	$	—	$	44	$	(23)	$	—	$	21

Offsetting of financial assets and liabilities under netting arrangements at December 31, 2021 were as follows:



							Gross Amounts Not Offset in the Consolidated Balance Sheets
(in millions)	Gross Amounts Recognized		Gross Amount Offset in the Consolidated Balance Sheets		Net Amounts Presented in the Consolidated Balance Sheets		Financial Instruments		Cash Collateral Received/Pledged		Net Amount

Assets
Foreign exchange forward contracts	$	31	$	—	$	31	$	(9)	$	—	$	22



Total assets	$	31	$	—	$	31	$	(9)	$	—	$	22

Liabilities
Foreign exchange forward contracts	$	4	$	—	$	4	$	(4)	$	—	$	—

Interest rate swaps	4		—		4		(2)		—		2
Cross currency basis swaps	4		—		4		(3)		—		1

Total liabilities	$	12	$	—	$	12	$	(9)	$	—	$	3

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959

+ Details

FAIR VALUE MEASUREMENT (Tables)

9 Months Ended

Sep. 30, 2022

Fair Value Disclosures [Abstract]

Schedule of Assets and Liabilities at Fair Value

The Company’s financial assets and liabilities set forth by level within the fair value hierarchy that were accounted for at fair value on a recurring basis were as follows:



	September 30, 2022
(in millions)	Total		Level 1		Level 2		Level 3

Assets



Cross currency basis swaps	$	43	$	—	$	43	$	—
Foreign exchange forward contracts	70		—		70		—
Long-term debt	36		—		36		—
Total assets	$	149	$	—	$	149	$	—

Liabilities
Interest rate swaps	$	36	$	—	$	36	$	—


Foreign exchange forward contracts	8		—		8		—

Contingent considerations on acquisitions	4		—		—		4
Total liabilities	$	48	$	—	$	44	$	4



	December 31, 2021
(in millions)	Total		Level 1		Level 2		Level 3

Assets

Interest rate swaps	$	5	$	—	$	5	$	—

Long-term debt	4		—		4		—
Cross currency basis swaps	4		—		4		—
Foreign exchange forward contracts	30		—		30		—

Total assets	$	43	$	—	$	43	$	—

Liabilities
Interest rate swaps	$	9	$	—	$	9	$	—

Cross currency basis swaps	7		—		7		—
Foreign exchange forward contracts	4		—		4		—

Contingent considerations on acquisitions	10		—		—		10

Total liabilities	$	30	$	—	$	20	$	10

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

A reconciliation of changes in the Company’s goodwill by reportable segment were as follows:


(in millions)	Technologies & Equipment		Consumables		Total

Balance at December 31, 2021
Goodwill	$	5,989	$	880	$	6,869
Accumulated impairment losses	(2,893)		—		(2,893)
Goodwill, net	$	3,096	$	880	$	3,976


Impairment	(1,187)		—		(1,187)
Translation and other	(170)		(35)		(205)

Balance at September 30, 2022
Goodwill	$	5,819	$	845	$	6,664
Accumulated impairment losses	(4,080)		—		(4,080)
Goodwill, net	$	1,739	$	845	$	2,584

Schedule of Definite-lived and Indefinite-lived Intangible Assets

Identifiable definite-lived and indefinite-lived intangible assets were as follows:


	September 30, 2022						December 31, 2021
(in millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount

Developed technology and patents	$	1,569	$	(764)	$	805	$	1,729	$	(762)	$	967
Tradenames and trademarks	269		(90)		179		269		(79)		190
Licensing agreements	31		(26)		5		36		(32)		4
Customer relationships	1,005		(553)		452		1,091		(545)		546
Total definite-lived	$	2,874	$	(1,433)	$	1,441	$	3,125	$	(1,418)	$	1,707

Indefinite-lived tradenames and trademarks	$	426	$	—	$	426	$	598	$	—	$	598
In-process R&D (a)	8		—		8		14		—		14
Total indefinite-lived	$	434	$	—	$	434	$	612	$	—	$	612

Total identifiable intangible assets	$	3,308	$	(1,433)	$	1,875	$	3,737	$	(1,418)	$	2,319

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2022

Commitments and Contingencies Disclosure [Abstract]

Long-term Purchase Commitment


(in millions)


2022	$	66
2023	175
2024	77
2025	58
2026	69
Thereafter	—
Total	$	445

The above information should be read in conjunction with Part II, Item 7 “Contractual Obligations” and Part II, Item 8, Note 22 “Commitments and Contingencies” in our 2021 Form 10-K/A.

SIGNIFICANT ACCOUNTING POLICIES AND RESTATEMENT - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ (947)	$ (1,040)	$ (2,939)	$ (3,128)
Gross profit	(508)	(569)	(1,610)	(1,743)
Operating income	$ 1,218	$ (132)	$ 1,002	$ (436)
Diluted (in dollars per share)	$ 5.01	$ (0.38)	$ 4.34	$ (1.32)
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales		$ 29		$ 35
Gross profit		22		25
Operating income		$ 27		$ 32
Diluted (in dollars per share)		$ 0.09		$ 0.13
Adjustment \| Certain Product Returns and/or Exchanges
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales		$ 4

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

REVENUE (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
REVENUE (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 947	$ 1,040	$ 2,939	$ 3,128
Deferred revenue	74		74		$ 68
Deferred revenue recognized during the year			48
Trade Accounts Receivable
Disaggregation of Revenue [Line Items]
Allowance for doubtful accounts and trade discounts	9		9		$ 13
United States \| Geographical Basis, Country of Sales
Disaggregation of Revenue [Line Items]
Net sales	357	384	1,023	1,094
Europe \| Geographical Basis, Country of Sales
Disaggregation of Revenue [Line Items]
Net sales	358	393	1,183	1,239
Rest of World \| Geographical Basis, Country of Sales
Disaggregation of Revenue [Line Items]
Net sales	232	263	733	795
Technology & Equipment segment revenue
Disaggregation of Revenue [Line Items]
Net sales	556	612	1,716	1,824
Technology & Equipment segment revenue \| Equipment & Instruments
Disaggregation of Revenue [Line Items]
Net sales	163	176	498	523
Technology & Equipment segment revenue \| CAD/CAM
Disaggregation of Revenue [Line Items]
Net sales	116	147	351	403
Technology & Equipment segment revenue \| Orthodontics
Disaggregation of Revenue [Line Items]
Net sales	76	63	220	212
Technology & Equipment segment revenue \| Implants
Disaggregation of Revenue [Line Items]
Net sales	135	150	439	461
Technology & Equipment segment revenue \| Healthcare
Disaggregation of Revenue [Line Items]
Net sales	66	76	208	225
Consumables segment revenue
Disaggregation of Revenue [Line Items]
Net sales	391	428	1,223	1,304
Consumables segment revenue \| Endodontic & Restorative
Disaggregation of Revenue [Line Items]
Net sales	282	313	887	953
Consumables segment revenue \| Other Consumables
Disaggregation of Revenue [Line Items]
Net sales	$ 109	$ 115	$ 336	$ 351

STOCK COMPENSATION (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
STOCK COMPENSATION (Details) - USD ($) $ in Millions	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	$ 14	$ 22	$ 47	$ 54
Related deferred income tax benefit	1	2	4	6
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	1	2	2	4
Selling, general, and administrative expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	12	19	43	48
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock based compensation expense	$ 1	$ 1	$ 2	$ 2

COMPREHENSIVE INCOME (LOSS) - BALANCES INCLUDED IN AOCI, NET OF TAX, IN THE CONSOLIDATED BALANCE SHEETS (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	$ 4,838	$ 4,864	$ 4,997	$ 5,034	$ 4,890	$ 4,935	$ 4,997	$ 4,935
Tax (expense) benefit		0
Total other comprehensive loss, net of tax	(125)	(90)	(37)	(56)	43	(90)	(252)	(103)
Ending Balance	3,614	4,838	4,864	5,063	5,034	4,890	3,614	5,063
Accumulated Other Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(719)	(629)	(592)	(511)	(554)	(464)	(592)	(464)
Other comprehensive (loss) income before reclassifications and tax impact	(89)	(57)	(25)	(50)	35	(68)
Tax (expense) benefit	(36)	(36)	(12)	(11)	3	(26)
Other comprehensive (loss) income, net of tax, before reclassifications	(125)	(93)	(37)	(61)	38	(94)
Amounts reclassified from accumulated other comprehensive income, net of tax	0	3	0	5	5	4
Total other comprehensive loss, net of tax	(125)	(90)	(37)	(56)	43	(90)
Ending Balance	(844)	(719)	(629)	(567)	(511)	(554)	(844)	(567)
Foreign Currency Translation Gain (Loss)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(528)	(414)	(366)	(249)	(286)	(187)	(366)	(187)
Other comprehensive (loss) income before reclassifications and tax impact	(120)	(86)	(37)	(59)	31	(74)
Tax (expense) benefit	(28)	(28)	(11)	(9)	6	(25)
Other comprehensive (loss) income, net of tax, before reclassifications	(148)	(114)	(48)	(68)	37	(99)
Amounts reclassified from accumulated other comprehensive income, net of tax	0	0	0	0	0	0
Total other comprehensive loss, net of tax	(148)	(114)	(48)	(68)	37	(99)
Ending Balance	(676)	(528)	(414)	(317)	(249)	(286)	(676)	(317)
Gain (Loss) on Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(16)	(14)	(16)	(23)	(27)	(25)	(16)	(25)
Other comprehensive (loss) income before reclassifications and tax impact	3	(3)	3	6	3	(6)
Tax (expense) benefit	(1)	0	0	(1)	(2)	2
Other comprehensive (loss) income, net of tax, before reclassifications	2	(3)	3	5	1	(4)
Amounts reclassified from accumulated other comprehensive income, net of tax	(1)	1	(1)	3	3	2
Total other comprehensive loss, net of tax	1	(2)	2	8	4	(2)
Ending Balance	(15)	(16)	(14)	(15)	(23)	(27)	(15)	(15)
Gain (Loss) on Net Investment and Fair Value Hedges
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(71)	(95)	(103)	(112)	(112)	(119)	(103)	(119)
Other comprehensive (loss) income before reclassifications and tax impact	28	32	9	3	1	9
Tax (expense) benefit	(7)	(8)	(1)	(1)	(1)	(2)
Other comprehensive (loss) income, net of tax, before reclassifications	21	24	8	2	0	7
Amounts reclassified from accumulated other comprehensive income, net of tax	0	0	0	0	0	0
Total other comprehensive loss, net of tax	21	24	8	2	0	7
Ending Balance	(50)	(71)	(95)	(110)	(112)	(112)	(50)	(110)
Pension Liability Gain (Loss)
Accumulated Other Comprehensive Income (Loss) [Roll Forward]
Beginning Balance	(104)	(106)	(107)	(127)	(129)	(133)	(107)	(133)
Other comprehensive (loss) income before reclassifications and tax impact	0	0	0	0	0	3
Tax (expense) benefit	0		0	0	0	(1)
Other comprehensive (loss) income, net of tax, before reclassifications	0	0	0	0	0	2
Amounts reclassified from accumulated other comprehensive income, net of tax	1	2	1	2	2	2
Total other comprehensive loss, net of tax	1	2	1	2	2	4
Ending Balance	$ (103)	$ (104)	$ (106)	$ (125)	$ (127)	$ (129)	$ (103)	$ (125)

COMPREHENSIVE INCOME (LOSS) - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Derivative [Line Items]
Equity	$ 3,614	$ 4,838	$ 4,864	$ 4,997	$ 5,063	$ 5,034	$ 4,890	$ 4,935
Foreign Currency Translation Gain (Loss)
Derivative [Line Items]
Foreign currency tax adjustment	84			168
Equity	(676)	$ (528)	$ (414)	(366)	$ (317)	$ (249)	$ (286)	$ (187)
Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest, Translation Gain (Loss)
Derivative [Line Items]
Equity	(639)			(250)
Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest, Net Investment Hedges
Derivative [Line Items]
Equity	$ (37)			$ (116)

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

+ Details

EARNINGS PER COMMON SHARE - EARNINGS PER SHARE COMPUTATION (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Basic Earnings Per Common Share
Net (loss) income attributable to Dentsply Sirona	$ (1,077)	$ 84	$ (935)	$ 292
Weighted average common shares outstanding (in shares)	214.9	218.6	215.6	218.6
(Loss) earnings per common share - basic (in dollars per share)	$ (5.01)	$ 0.39	$ (4.34)	$ 1.34
Diluted Earnings Per Common Share
Net (loss) income attributable to Dentsply Sirona	$ (1,077)	$ 84	$ (935)	$ 292
Weighted average common shares outstanding (in shares)	214.9	218.6	215.6	218.6
Incremental weighted average shares from assumed exercise of dilutive options from stock-based compensation awards (in shares)	0.0	1.9	0.0	2.1
Total weighted average diluted shares outstanding (in shares)	214.9	220.5	215.6	220.7
(Loss) earnings per common share - diluted (in dollars per share)	$ (5.01)	$ 0.38	$ (4.34)	$ 1.32

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

EARNINGS PER COMMON SHARE - ADDITIONAL INFORMATION (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Mar. 09, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive common stock options not included in the computation of diluted earnings per common share (in shares)	300,000		500,000
Stock repurchase program, authorized amount	$ 1,000,000,000		$ 1,000,000,000
Stock repurchase program, number of shares authorized to be repurchased	740,000,000		740,000,000
Accelerated share repurchases, delivery of common shares					$ 120,000,000
Stock Options and RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive common stock options not included in the computation of diluted earnings per common share (in shares)	3,600,000	900,000	3,600,000	900,000

EARNINGS PER COMMON SHARE - ACCELERATED SHARE REPURCHASE PROGRAM (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Apr. 19, 2022	Mar. 08, 2022
Earnings Per Share [Abstract]
Payments for accelerated share repurchase program		$ (150)
Initial Delivery [Abstract]
Shares received (in shares)		2.4
Price per share (in USD per share)		$ 50.44
Value of Shares as a % of Contract Value		80.00%
Final Settlement [Abstract]
Total Shares Received (in shares)	3.1
Average Price per Share (in usd per share)	$ 48.22

BUSINESS COMBINATIONS - ADDITIONAL INFORMATION (Details) - USD ($)							9 Months Ended
	Jul. 01, 2021	Jun. 04, 2021	Jun. 01, 2021	Apr. 01, 2021	Feb. 01, 2021	Jan. 21, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Goodwill							$ 2,584,000,000		$ 3,976,000,000
Proceeds from divestiture of business							0	$ 27,000,000
Gain on sale of business							0	14,000,000
United Kingdom
Business Acquisition [Line Items]
Payments to acquire equity method investments		$ 16,000,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Digital Dentistry Business
Business Acquisition [Line Items]
Proceeds from divestiture of business				$ 8,000,000
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| Investment Casting Business
Business Acquisition [Line Items]
Proceeds from divestiture of business					$ 19,000,000
Gain on sale of business								$ 13,000,000
Dental Business \| Switzerland
Business Acquisition [Line Items]
Total acquisition consideration	$ 7,000,000
Other current assets	4,000,000
Intangible assets	3,000,000
Current liabilities	2,000,000
Other long term liabilities	1,000,000
Fair value of the previously-held interest	4,000,000
Goodwill	$ 7,000,000
Goodwill, period increase (decrease)							2,000,000
Propel Orthodontics
Business Acquisition [Line Items]
Other current assets			$ 4,000,000
Intangible assets			66,000,000
Current liabilities			1,000,000
Goodwill			63,000,000
Payments to acquire businesses, gross			$ 132,000,000
Increase (decrease) in goodwill							2,000,000
Datum Dental, Ltd
Business Acquisition [Line Items]
Total acquisition consideration						$ 103,000,000
Other current assets						2,000,000
Intangible assets						76,000,000
Current liabilities						2,000,000
Goodwill						39,000,000
Payments to acquire businesses, gross						94,000,000
Increase (decrease) in goodwill							(6,000,000)
Business combination, contingent consideration arrangements, range of outcomes, value, high						$ 10,000,000
Percentage of voting interest acquired						100.00%
Cash payments							5,000,000
Consideration based on earn out						$ 9,000,000	$ 4,000,000

BUSINESS COMBINATIONS - FAIR VALUES OF ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021	Jun. 01, 2021	Jan. 21, 2021
Business Acquisition [Line Items]
Goodwill	$ 2,584	$ 3,976
Propel Orthodontics
Business Acquisition [Line Items]
Other current assets			$ 4
Intangible assets			66
Current liabilities			(1)
Net assets acquired			69
Goodwill			63
Purchase consideration			$ 132
Datum Dental, Ltd
Business Acquisition [Line Items]
Cash and cash equivalents				$ 2
Other current assets				2
Intangible assets				76
Current liabilities				(2)
Other long-term assets (liabilities), net				(14)
Net assets acquired				64
Goodwill				39
Purchase consideration				$ 103

BUSINESS COMBINATIONS - SUMMARY OF INTANGIBLE ASSETS (Details) - USD ($) $ in Millions	Jul. 01, 2021	Jun. 01, 2021	Jan. 21, 2021
Propel Orthodontics
Acquired Indefinite-lived Intangible Assets [Line Items]
Intangible assets		$ 66
Datum Dental, Ltd
Acquired Indefinite-lived Intangible Assets [Line Items]
Intangible assets			$ 76
In-process R&D
Acquired Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets acquired, amount	$ 3
In-process R&D \| Datum Dental, Ltd
Acquired Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets acquired, amount			10
Developed technology \| Propel Orthodontics
Acquired Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired, amount		$ 66
Weighted average useful life (in years)		10 years
Developed technology \| Datum Dental, Ltd
Acquired Indefinite-lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired, amount			$ 66
Weighted average useful life (in years)			15 years

SEGMENT INFORMATION - ADDITIONAL INFORMATION (Details)	9 Months Ended
SEGMENT INFORMATION - ADDITIONAL INFORMATION (Details)	Sep. 30, 2022 segment
Segment Reporting [Abstract]
Number of operating groups	2

SEGMENT INFORMATION - THIRD PARTY NET SALES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue, Major Customer [Line Items]
Net sales	$ 947	$ 1,040	$ 2,939	$ 3,128
Technologies & Equipment
Revenue, Major Customer [Line Items]
Net sales	556	612	1,716	1,824
Consumables
Revenue, Major Customer [Line Items]
Net sales	$ 391	$ 428	$ 1,223	$ 1,304

- Definition

+ References

+ Details

SEGMENT INFORMATION - SEGMENT ADJUSTED OPERATING INCOME (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Reconciling items expense (income):
Segment adjusted operating income	$ (1,218)	$ 132	$ (1,002)	$ 436
Goodwill impairment	1,187	0	1,187	0
Intangible asset impairment and other costs	97	3	107	11
Other expense (income), net	9	5	20	4
Amortization of intangible assets			159	167
(Loss) income before income taxes	(1,241)	113	(1,063)	389
Technologies & Equipment
Reconciling items expense (income):
Goodwill impairment			1,187
Consumables
Reconciling items expense (income):
Goodwill impairment			0
Operating Segments
Reconciling items expense (income):
Segment adjusted operating income	194	257	676	817
Operating Segments \| Technologies & Equipment
Reconciling items expense (income):
Segment adjusted operating income	73	134	278	391
Operating Segments \| Consumables
Reconciling items expense (income):
Segment adjusted operating income	121	123	398	426
All Other
Reconciling items expense (income):
All other	77	67	223	199
Segment Reconciling Items
Reconciling items expense (income):
Goodwill impairment	1,187	0	1,187	0
Intangible asset impairment and other costs	97	3	107	11
Interest expense, net	14	14	41	43
Other expense (income), net	9	5	20	4
Amortization of intangible assets	51	56	159	167
Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations	$ 0	$ (1)	$ 2	$ 4

INVENTORIES - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory valuation reserve	$ 77	$ 86

INVENTORIES - SUMMARY OF INVENTORY (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 142	$ 139
Work-in-process	70	72
Finished goods	380	304
Inventories, net	$ 592	$ 515

INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS - CONSOLIDATED STATEMENTS OF OPERATIONS (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Restructuring Cost and Reserve [Line Items]
Total intangible asset impairment and other costs	$ 97	$ 6	$ 107	$ 14
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Total intangible asset impairment and other costs	0	0	0	(3)
Selling, general, and administrative expenses
Restructuring Cost and Reserve [Line Items]
Total intangible asset impairment and other costs	0	3	0	6
Intangible asset impairment and other costs
Restructuring Cost and Reserve [Line Items]
Total intangible asset impairment and other costs	$ 97	$ 3	$ 107	$ 11

INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Technologies & Equipment Segment and Consumables Segment
Restructuring Cost and Reserve [Line Items]
Impairment charge	$ 94	$ 94

INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS - RESTRUCTURING ACCURALS (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 18
Amounts applied	(17)
Change in estimates	(1)
Ending Balance	13
Severance
Restructuring Reserve [Roll Forward]
Beginning Balance	14
Provisions	10
Amounts applied	(11)
Change in estimates	(1)
Ending Balance	12
Severance \| 2020 and Prior Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	5
Provisions	1
Amounts applied	(3)
Change in estimates	(1)
Ending Balance	2
Severance \| 2021 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	9
Provisions	1
Amounts applied	(5)
Change in estimates	0
Ending Balance	5
Severance \| 2022 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Provisions	8
Amounts applied	(3)
Change in estimates	0
Ending Balance	5
Other Restructuring Costs
Restructuring Reserve [Roll Forward]
Beginning Balance	4
Provisions	3
Amounts applied	(6)
Ending Balance	1
Other Restructuring Costs \| 2020 and Prior Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	4
Provisions	1
Amounts applied	(4)
Ending Balance	1
Other Restructuring Costs \| 2021 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Provisions	1
Amounts applied	(1)
Ending Balance	0
Other Restructuring Costs \| 2022 Plans
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Provisions	1
Amounts applied	(1)
Ending Balance	$ 0

INTANGIBLE ASSET IMPAIRMENT AND OTHER COSTS - PROVISIONS AND ADJUSTMENTS AND AMOUNTS APPLIED FOR ALL PLANS BY SEGMENT (Details) $ in Millions	9 Months Ended
	Sep. 30, 2022 USD ($)
Restructuring Reserve [Roll Forward]
Beginning Balance	$ 18
Provisions	13
Amounts applied	(17)
Change in estimates	(1)
Ending Balance	13
Operating Segments \| Technologies & Equipment
Restructuring Reserve [Roll Forward]
Beginning Balance	7
Provisions	3
Amounts applied	(6)
Change in estimates	0
Ending Balance	4
Operating Segments \| Consumables
Restructuring Reserve [Roll Forward]
Beginning Balance	11
Provisions	7
Amounts applied	(8)
Change in estimates	(1)
Ending Balance	9
All Other
Restructuring Reserve [Roll Forward]
Beginning Balance	0
Provisions	3
Amounts applied	(3)
Change in estimates	0
Ending Balance	$ 0

FINANCIAL INSTRUMENTS AND DERIVATIVES - SUMMARY OF DERIVATIVE INSTRUMENTS (Details) - USD ($) $ in Millions	Sep. 30, 2022	Jul. 01, 2021
Interest rate swaps
Derivative [Line Items]
Aggregate Notional Amount		$ 250
Not Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	$ 27
Aggregate Notional Amount Maturing within 12 Months	27
Not Designated as Hedging Instrument \| Foreign exchange forward contracts
Derivative [Line Items]
Aggregate Notional Amount	27
Aggregate Notional Amount Maturing within 12 Months	27
Cash Flow Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	85
Aggregate Notional Amount Maturing within 12 Months	79
Cash Flow Hedges \| Designated as Hedging Instrument \| Foreign exchange forward contracts
Derivative [Line Items]
Aggregate Notional Amount	85
Aggregate Notional Amount Maturing within 12 Months	79
Hedges of Net Investments \| Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	419
Aggregate Notional Amount Maturing within 12 Months	78
Hedges of Net Investments \| Designated as Hedging Instrument \| Foreign exchange forward contracts
Derivative [Line Items]
Aggregate Notional Amount	157
Aggregate Notional Amount Maturing within 12 Months	78
Hedges of Net Investments \| Designated as Hedging Instrument \| Cross currency basis swaps
Derivative [Line Items]
Aggregate Notional Amount	262
Aggregate Notional Amount Maturing within 12 Months	0
Fair Value Hedges \| Designated as Hedging Instrument
Derivative [Line Items]
Aggregate Notional Amount	378
Aggregate Notional Amount Maturing within 12 Months	49
Fair Value Hedges \| Designated as Hedging Instrument \| Foreign exchange forward contracts
Derivative [Line Items]
Aggregate Notional Amount	128
Aggregate Notional Amount Maturing within 12 Months	49
Fair Value Hedges \| Designated as Hedging Instrument \| Interest rate swaps
Derivative [Line Items]
Aggregate Notional Amount	250
Aggregate Notional Amount Maturing within 12 Months	$ 0

FINANCIAL INSTRUMENTS AND DERIVATIVES - ADDITIONAL INFORMATION (Details) € in Millions, kr in Billions			3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 01, 2021 USD ($)	May 26, 2020 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2022 EUR (€)	Jul. 02, 2021 USD ($)	May 25, 2021 EUR (€) performancePeriod	Jan. 06, 2021 SEK (kr)
Derivative [Line Items]
Net gain on derivative financial instruments			$ 22,000,000	$ 10,000,000	$ 54,000,000	$ 19,000,000
Senior Unsecured Notes Maturing June 1, 2030 \| Senior Notes
Derivative [Line Items]
Debt instrument, face amount	$ 750,000,000	$ 750,000,000
Debt instrument, interest rate, stated percentage	3.30%								1.70%
Designated as Hedging Instrument \| Hedges of Net Investments
Derivative [Line Items]
Derivative, notional amount			419,000,000		419,000,000
Designated as Hedging Instrument \| Cash Flow Hedges
Derivative [Line Items]
Derivative, notional amount			$ 85,000,000		$ 85,000,000
Foreign exchange forward contracts
Derivative [Line Items]
Derivative, term of contract					18 months
Derivative, notional amount \| kr											kr 1.3
Foreign exchange forward contracts \| Designated as Hedging Instrument \| Hedges of Net Investments
Derivative [Line Items]
Derivative, notional amount \| €								€ 160		€ 10
Foreign exchange forward contracts \| performancePeriod										8
Cross Currency Interest Rate Contract
Derivative [Line Items]
Derivative, notional amount									$ 300,000,000
Interest rate swaps
Derivative [Line Items]
Derivative, notional amount	$ 250,000,000
Interest Rate Swap Maturing June 1, 2026
Derivative [Line Items]
Derivative, term of contract	5 years
Derivative, notional amount	$ 100,000,000
Interest Rate Swap Maturing March 1, 2030
Derivative [Line Items]
Derivative, term of contract	9 years
Derivative, notional amount	$ 150,000,000
Treasury Lock \| Cash Flow Hedges
Derivative [Line Items]
Repayments of debt		31,000,000
Derivative, notional amount		$ 150,000,000
Long-term debt, term		10 years
Net gain on derivative financial instruments					$ 23,000,000		$ 25,000,000

FINANCIAL INSTRUMENTS AND DERIVATIVES - DERIVATIVE INSTRUMENTS - GAIN (LOSS) RECORDED IN AOCI IN THE CONSOLIDATED BALANCE SHEETS (Details) - Designated as Hedging Instrument - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Cash Flow Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) recognized in AOCI	$ 3	$ 6	$ 3	$ 3
Effective Portion Reclassified from AOCI into Income (Expense)	1	(3)	1	(8)
Recognized in Income (Expense)	0	0	0	1
Cash Flow Hedges \| Foreign exchange forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) recognized in AOCI	3	6	3	3
Effective Portion Reclassified from AOCI into Income (Expense)	1	(2)	3	(4)
Recognized in Income (Expense)	0	0	0	1
Cash Flow Hedges \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) recognized in AOCI	0	0	0	0
Effective Portion Reclassified from AOCI into Income (Expense)	0	(1)	(2)	(4)
Recognized in Income (Expense)	0	0	0	0
Hedges of Net Investments
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) recognized in AOCI	29	3	71	13
Effective Portion Reclassified from AOCI into Income (Expense)	0	0	0	0
Recognized in Income (Expense)	2	1	5	5
Hedges of Net Investments \| Foreign exchange forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) recognized in AOCI	11	4	24	7
Effective Portion Reclassified from AOCI into Income (Expense)	0	0	0	0
Recognized in Income (Expense)	0	0	1	0
Hedges of Net Investments \| Cross currency basis swaps
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) recognized in AOCI	18	(1)	47	6
Effective Portion Reclassified from AOCI into Income (Expense)	0	0	0	0
Recognized in Income (Expense)	2	1	4	5
Fair Value Hedges
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) recognized in AOCI	(1)	0	(2)	0
Effective Portion Reclassified from AOCI into Income (Expense)	0	0	0	0
Recognized in Income (Expense)	12	7	37	19
Fair Value Hedges \| Foreign exchange forward contracts
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) recognized in AOCI	(1)	0	(2)	0
Effective Portion Reclassified from AOCI into Income (Expense)	0	0	0	0
Recognized in Income (Expense)	13	6	37	18
Fair Value Hedges \| Interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Gain (Loss) recognized in AOCI	0	0	0	0
Effective Portion Reclassified from AOCI into Income (Expense)	0	0	0	0
Recognized in Income (Expense)	$ (1)	$ 1	$ 0	$ 1

FINANCIAL INSTRUMENTS AND DERIVATIVES - BALANCE SHEET ALLOCATION (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	$ 113	$ 31
Gross liability amount recognized for derivative instruments designated as hedges	44	12
Interest rate swaps
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	36	4
Cross currency basis swaps
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	43
Gross liability amount recognized for derivative instruments designated as hedges		4
Prepaid Expenses and Other Current Assets
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	40	27
Gross asset amount recognized for derivative instruments not designated as hedges	4	1
Prepaid Expenses and Other Current Assets \| Foreign exchange forward contracts \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	37	18
Prepaid Expenses and Other Current Assets \| Foreign exchange forward contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments not designated as hedges	4	1
Prepaid Expenses and Other Current Assets \| Interest rate swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0	5
Prepaid Expenses and Other Current Assets \| Cross currency basis swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	3	4
Other Noncurrent Assets
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	69	11
Gross asset amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Assets \| Foreign exchange forward contracts \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	29	11
Other Noncurrent Assets \| Foreign exchange forward contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Assets \| Interest rate swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	0	0
Other Noncurrent Assets \| Cross currency basis swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross asset amount recognized for derivative instruments designated as hedges	40	0
Accrued Liabilities
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	11	2
Gross liability amount recognized for derivative instruments not designated as hedges	3	1
Accrued Liabilities \| Foreign exchange forward contracts \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	2	2
Accrued Liabilities \| Foreign exchange forward contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments not designated as hedges	3	1
Accrued Liabilities \| Interest rate swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	9	0
Accrued Liabilities \| Cross currency basis swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	0	0
Other Noncurrent Liabilities
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	30	17
Gross liability amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Liabilities \| Foreign exchange forward contracts \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	3	1
Other Noncurrent Liabilities \| Foreign exchange forward contracts \| Not Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments not designated as hedges	0	0
Other Noncurrent Liabilities \| Interest rate swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	27	9
Other Noncurrent Liabilities \| Cross currency basis swaps \| Designated as Hedging Instrument
Derivative [Line Items]
Gross liability amount recognized for derivative instruments designated as hedges	$ 0	$ 7

FINANCIAL INSTRUMENTS AND DERIVATIVES - BALANCE SHEET OFFSETTING (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Assets
Gross Amounts Recognized	$ 113	$ 31
Gross Amount Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	113	31
Financial Instruments	(23)	(9)
Cash Collateral Received/Pledged	0	0
Net Amount	90	22
Liabilities
Gross Amounts Recognized	44	12
Gross Amount Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	44	12
Financial Instruments	(23)	(9)
Cash Collateral Received/Pledged	0	0
Net Amount	21	3
Foreign exchange forward contracts
Assets
Gross Amounts Recognized	70	31
Gross Amount Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	70	31
Financial Instruments	(6)	(9)
Cash Collateral Received/Pledged	0	0
Net Amount	64	22
Liabilities
Gross Amounts Recognized	8	4
Gross Amount Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	8	4
Financial Instruments	(8)	(4)
Cash Collateral Received/Pledged	0	0
Net Amount	0	0
Cross currency basis swaps
Assets
Gross Amounts Recognized	43
Gross Amount Offset in the Consolidated Balance Sheets	0
Net Amounts Presented in the Consolidated Balance Sheets	43
Financial Instruments	(17)
Cash Collateral Received/Pledged	0
Net Amount	26
Liabilities
Gross Amounts Recognized		4
Gross Amount Offset in the Consolidated Balance Sheets		0
Net Amounts Presented in the Consolidated Balance Sheets		4
Financial Instruments		(3)
Cash Collateral Received/Pledged		0
Net Amount		1
Interest rate swaps
Liabilities
Gross Amounts Recognized	36	4
Gross Amount Offset in the Consolidated Balance Sheets	0	0
Net Amounts Presented in the Consolidated Balance Sheets	36	4
Financial Instruments	(15)	(2)
Cash Collateral Received/Pledged	0	0
Net Amount	$ 21	$ 2

FAIR VALUE MEASUREMENT - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Estimate of Fair Value, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	$ 1,794	$ 2,239
Carrying (Reported) Amount, Fair Value Disclosure
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt	$ 1,983	$ 2,095

FAIR VALUE MEASUREMENT - ASSETS AND LIABILITIES, RECURRING (Details) - Fair Value, Recurring - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	$ 149	$ 43
Liabilities	48	30
Cross currency basis swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	43	4
Liabilities		7
Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets		5
Liabilities	36	9
Foreign exchange forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	70	30
Liabilities	8	4
Long-term debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	36	4
Contingent considerations on acquisitions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	4	10
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities	0	0
Level 1 \| Cross currency basis swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities		0
Level 1 \| Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets		0
Liabilities	0	0
Level 1 \| Foreign exchange forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities	0	0
Level 1 \| Long-term debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 1 \| Contingent considerations on acquisitions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0	0
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	149	43
Liabilities	44	20
Level 2 \| Cross currency basis swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	43	4
Liabilities		7
Level 2 \| Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets		5
Liabilities	36	9
Level 2 \| Foreign exchange forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	70	30
Liabilities	8	4
Level 2 \| Long-term debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	36	4
Level 2 \| Contingent considerations on acquisitions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	0	0
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities	4	10
Level 3 \| Cross currency basis swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities		0
Level 3 \| Interest rate swaps
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets		0
Liabilities	0	0
Level 3 \| Foreign exchange forward contracts
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Liabilities	0	0
Level 3 \| Long-term debt
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets	0	0
Level 3 \| Contingent considerations on acquisitions
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Liabilities	$ 4	$ 10

INCOME TAXES - ADDITIONAL INFORMATION (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2023
Income Tax Examination [Line Items]
Tax expense (benefit) for other discrete tax matters	$ 6	$ 4	$ 7	$ 11
Effective income tax rate reconciliation, nondeductible expense, impairment losses, amount			$ 183
Forecast
Income Tax Examination [Line Items]
Unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations					$ 1

FINANCING ARRANGEMENTS (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Line of Credit Facility [Line Items]
Borrowings available under lines of credit	$ 503,000,000
Notes payable and current portion of long-term debt	246,000,000	$ 182,000,000
Other short-term borrowings	$ 21,000,000
Debt, weighted average interest rate	4.00%
Commercial Paper
Line of Credit Facility [Line Items]
Notes payable and current portion of long-term debt	$ 224,000,000	170,000,000
Uncommitted Short-Term Financing
Line of Credit Facility [Line Items]
Notes payable and current portion of long-term debt	48,000,000
Line of Credit \| Commercial Paper
Line of Credit Facility [Line Items]
Maximum borrowing capacity	500,000,000
Line of Credit \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Maximum borrowing capacity	700,000,000
Notes payable and current portion of long-term debt	$ 0	$ 0

GOODWILL AND INTANGIBLE ASSETS - NARRATIVE (Details) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) reporting_unit	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Goodwill [Line Items]
Number of reporting units \| reporting_unit				2
Goodwill impairment	$ 1,187	$ 0		$ 1,187	$ 0
Underlying market interest rate increase	0.0200
Goodwill	$ 2,584			2,584		$ 3,976
Indefinite-lived intangible asset impairment				94	$ 0
Identifiable intangible assets, net	1,875			1,875		$ 2,319
Developed technology and patents
Goodwill [Line Items]
Payments to acquire intangible assets			$ 3
Asset acquisition, contingent consideration, liability	17			17
Digital Dental Group
Goodwill [Line Items]
Goodwill impairment	1,100
Goodwill	234			234
Indefinite-lived intangible asset impairment	66
Equipment & Instruments
Goodwill [Line Items]
Goodwill impairment	87
Goodwill	192			192
Indefinite-lived intangible asset impairment	26
Unimpaired Reporting Unit
Goodwill [Line Items]
Goodwill	$ 1,068			1,068
Goodwill impairment, sensitivity analysis, hypothetical increase in discount rate	0.0100
Goodwill impairment, sensitivity analysis, hypothetical fair value reduction, percentage	10.00%
Technologies & Equipment
Goodwill [Line Items]
Identifiable intangible assets, net	$ 43			43
Consumables
Goodwill [Line Items]
Indefinite-lived intangible asset impairment	2
Identifiable intangible assets, net	$ 30			$ 30

GOODWILL AND INTANGIBLE ASSETS - RECONCILIATION OF CHANGES IN GOODWILL (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Goodwill [Roll Forward]
Goodwill	$ 6,664		$ 6,664		$ 6,869
Accumulated impairment losses			(2,893)
Goodwill, net, beginning of the year			3,976
Goodwill impairment	(1,187)	$ 0	(1,187)	$ 0
Translation and other			(205)
Accumulated impairment losses	(4,080)		(4,080)
Goodwill, net, end of the year	2,584		2,584
Technologies & Equipment
Goodwill [Roll Forward]
Goodwill	5,819		5,819		5,989
Accumulated impairment losses			(2,893)
Goodwill, net, beginning of the year			3,096
Goodwill impairment			(1,187)
Translation and other			(170)
Accumulated impairment losses	(4,080)		(4,080)
Goodwill, net, end of the year	1,739		1,739
Consumables
Goodwill [Roll Forward]
Goodwill	845		845		$ 880
Accumulated impairment losses			0
Goodwill, net, beginning of the year			880
Goodwill impairment			0
Translation and other			(35)
Accumulated impairment losses	0		0
Goodwill, net, end of the year	$ 845		$ 845

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

GOODWILL AND INTANGIBLE ASSETS - IDENTIFIABLE DEFINITE-LIVED AND INDEFINITE-LIVED INTANGIBLE ASSETS (Details) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived tradenames and trademarks	$ 434	$ 612
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	2,874	3,125
Accumulated Amortization	(1,433)	(1,418)
Net Carrying Amount	1,441	1,707
Total identifiable intangible assets, Gross Carrying Amount	3,308	3,737
Identifiable intangible assets, net	1,875	2,319
Tradenames and trademarks
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived tradenames and trademarks	426	598
In-process R&D
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived tradenames and trademarks	8	14
Developed technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,569	1,729
Accumulated Amortization	(764)	(762)
Net Carrying Amount	805	967
Tradenames and trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	269	269
Accumulated Amortization	(90)	(79)
Net Carrying Amount	179	190
Licensing agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	31	36
Accumulated Amortization	(26)	(32)
Net Carrying Amount	5	4
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,005	1,091
Accumulated Amortization	(553)	(545)
Net Carrying Amount	452	$ 546
In Service Assets
Finite-Lived Intangible Assets [Line Items]
Net Carrying Amount	$ 5

COMMITMENTS AND CONTINGENCIES - ADDITIONAL INFORMATION (Details)		2 Months Ended	9 Months Ended
	Nov. 05, 2018 USD ($)	Aug. 09, 2018 lawsuit	Sep. 30, 2022 USD ($)
Loss Contingencies [Line Items]
Loss contingency, new claims filed, number \| lawsuit		2
Income tax penalties			$ 546,000,000
IRS \| Tax Year 2012
Loss Contingencies [Line Items]
Liability (refund) from income tax examination			(5,000,000)
IRS \| Tax Year 2013
Loss Contingencies [Line Items]
Liability (refund) from income tax examination			0
IRS \| Tax Year 2014
Loss Contingencies [Line Items]
Liability (refund) from income tax examination			17,000,000
Swedish Tax Agency
Loss Contingencies [Line Items]
Income tax examination, estimate of possible loss	$ 7,000,000		$ 36,000,000

COMMITMENTS AND CONTINGENCIES - PURCHASE COMMITMENTS (Details) $ in Millions	Sep. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022	$ 66
2023	175
2024	77
2025	58
2026	69
Thereafter	0
Total	$ 445